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                                            ABSTRACT 
A STUDY OF CARDIOVASCULAR AUTONOMIC FUNCTIONS AND 
SERUM LEPTIN LEVELS IN YOUNG OBESE INDIVIDUALS 
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Year        : 2014 – 2015 
Back ground:  
Over 312 million people are obese worldwide. Obesity has become a major 
nutritional health problem in India. It is associated with adverse cardiac events. 
Obesity is considered as a leading preventable cause of death.  Autonomic 
function tests are early non invasive tool to assess the cardiac distress. Adipose 
tissue acts as highly active metabolic and secretary endocrine organ. Leptin is one 
of the main adipocytokines secreted by the adipocytes. 
Aim & Objective:   
To study the cardiovascular autonomic functions and serum leptin levels in 
young obese individuals and to compare and correlate with normal individuals   
 Materials & Method:  
This case control study included 50 young obese subjects with BMI ≥ 25 kg 
/m2 and 50 controls with BMI 18.5 - 24.9 kg/m2 of age 18 to 25years. 25 males 
and 25 females were included in the obese and control group each.  After getting 
an informed consent, the weight, height, body mass index, waist circumference, 
hip circumference and waist hip ratio were measured. They were made to undergo 
Resting HRV using Niviqure Ambulatory ECG Recorder, Orthostatic standing 
test, Deep Breathing test, Valsalva maneuver, Isometric Hand Grip test and Cold 
Pressor test. 5 ml of venous blood was collected for estimating serum leptin levels 
by ELISA method.   The results obtained were analyzed with SPSS version 21 and 
compared with normal individuals using independent student t test. 
Result:  
The weight, body mass index, waist circumference, hip circumference and 
waist to hip ratio were all increased significantly in the young obese individuals. 
The resting systolic and diastolic blood pressure in obese group though within 
normal limits was significantly increased. In Resting HRV, the time domain 
measures SDNN was reduced, Mean HR was increased significantly in the obese 
group. The frequency domain measures LF nu and LF/HF ratio were increased and 
HF nu was reduced significantly in the young obese individuals. 
 In Orthostatic standing test 30/15 ratio was decreased, and the variation in 
SBP and DBP at 1 minute on standing was significantly more in the obese group. 
E/I ratio in deep breathing test, and Valsalva ratio were reduced significantly in 
the obese group. There was a significant increase in the variation of SBP and DBP 
in the Isometric test and DBP in Cold pressor test in the obese group.  In young 
obese individuals, Serum leptin levels are significantly higher correlating with 
BMI and waist circumference and with HRV parameters. 
All these results substantiate autonomic dysfunction with sympathetic 
predominance and parasympathetic withdrawal. 
Conclusion:  
Autonomic Function tests in young obese individuals indicate that there is a 
definite sympathovagal imbalance in the form of sympathetic over activity and 
parasympathetic withdrawal. Elevated serum leptin levels play a direct vital role in 
stimulating the sympathetic nervous system. Chronic activation of the sympathetic 
nervous system makes them more prone for adverse cardiovascular events.  
The battery of autonomic function tests is an effective tool in identifying 
the autonomic dysfunction at an earlier stage. Understanding the role of the 
sympathetic nervous system and the serum leptin levels in obesity might help in 
the treatment of obesity and prevent further complications in this disease. Early 
diagnosis, behavioral and life style modification, health education and medication, 
may alleviate such problems. 
Keywords: Young obese, Resting HRV, cardiovascular autonomic functions, 
Serum Leptin, sympathovagal balance. 
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 1. INTRODUCTION 
          Obesity is a nutritional health problem that has reached an epidemic 
proportion in our society. This is considered to be due to the development in 
socioeconomic status with advent of civilization, leading to change in life style 
especially in dietary pattern1. Earlier, obesity was an important nutritional disease 
in the developed countries. But now obesity is gradually increasing even in 
developing countries and all sections of population including children, adolescents 
and adults are affected2. World Health Organization documents state that 312 
million people are obese worldwide. 
 All definitions of obesity seem to be arbitrary because the weight 
distribution in the general population is a continuum rather than segregation into 
distinct populations of obese and non obese individuals. WHO defines obesity as 
“A condition with excessive fat accumulation in the body to an extent that health 
and wellbeing are adversely affected.” The definition of obesity is limited to body 
mass index.  
Body mass index (BMI) is an internationally accepted tool widely used to 
assess the obesity and it is an internationally accepted tool. BMI, a weight to 
height ratio, is calculated as weight in kilograms by height in meter square3.  
Present environment of excessive food availability and intake as compared 
to decreased physical activity favors an increase in adiposity. Thus an excessive 
[2] 
 
intake of calories in relation to energy expenditure which is termed as positive 
energy balance, over a long period of time leads on to obesity.  
Obesity was rare before the 20th century (Haslam et al, 2007).  The WHO 
formally recognized “obesity as a global epidemic in 1997” (Caballero, 2007).  At 
least 9.8% of the general population are obese, with higher occurence among 
women than men according to WHO in 2005. Obesity growing as an epidemic in 
many countries (Friedman and Fanning, 2004) has become a major public health 
problem (Friedrich, 2002), affecting a wide spectrum of age groups (Pischon et al, 
2008), from young to elderly (Bellows-Rieckel et al, 2008). Among children and 
adults the estimated prevalence ranges from 10 to 50 percent (Van Gaal et al, 
1995). The current International Obesity Task Force estimates suggest that, at least 
1.1 billion people are overweight worldwide and out of which 312 million of them 
are obese.  
Obesity is a pro inflammatory condition that increases cardiovascular 
morbidity and mortality risk by various mechanisms4,5,6.Obesity is associated with 
alterations both in hemodynamics and metabolic activity. Obese people have 
higher prevalence of co-morbidities like hypertension, hyperlipidemia, coronary 
heart disease, Type 2 diabetes mellitus, Sleep Apnea Syndrome, osteoarthritis, 
fatty liver, polycystic ovarian disease and neoplasms.  These co-morbid conditions 
are the cause of increased rate of death in obesity. Obesity forms a part of the 
metabolic syndrome, which is diagnosed by the presence of central obesity, 
[3] 
 
dyslipidemia, hypertension, insulin resistance who have a higher risk for type 2 
diabetes and cardiovascular diseases 7 . Early studies indicate that obesity is 
associated with sudden cardiac deaths 8 , 9 . Hence obesity is considered as a 
leading preventable cause of death worldwide (Ezekiel et al, 2008).  
Several approaches, which include direct techniques and indirect techniques 
have been taken to measure obesity. The direct techniques involve a number of 
procedures that include densitometry, measurement of total body potassium, 
estimation of total body water, neutron activation techniques, computed 
topography (CT scan), magnetic resonance imaging scans (MRI scans), electrical 
methods that measure conductivity and impedance.  
The indirect techniques for estimating total fat include skin fold 
measurements, weight to height ratios, waist circumference, waist to hip ratio and 
hip circumference.  
“Body weight above 20% of the ideal weight is obesity”. Height, age, sex 
and built of an individual are taken into account for ideal body weight.   
Waist Circumference is measured in centimeters at a level of umbilicus or 
midway between lower rib cage and pubic symphysis. It is also a good indicator of 
total body fat. It is the best anthropometric indicator of visceral fat. WC ≥ 102 cm 
in males and ≥ 88 cm in females indicates obesity.  
 
[4] 
 
“Waist Hip Ratio (WHR) is the ratio of waist circumference to hip 
circumference.” The hip circumference is measured as widest circumference at the 
level of greater trochanter. Though difficult to measure, WHR is a useful predictor 
of risk of cardiovascular disease and diabetes in adults. WHR ≥ 1.0 for males and 
WHR ≥ 0.9 for females indicates obesity. 
Skin fold thickness measures the subcutaneous fat that correlates with total 
body fat. Using skin calipers skin fold thickness is measured in mid triceps, 
biceps, supra iliac and supra scapular regions. Sum of these measurements more 
than 40 mm in males and more than 50 mm in females indicates obesity. 
In 1997, it was proposed that thresholds shown in the below table shall be 
used to classify overweight in adults according to BMI (WHO, 1998)  
        BMI      Classification  
< 18.50 Underweight 
18.50 – 24.99 Normal Range 
≥ 25.00 Overweight 
25.00 - 29.99 Pre obese  
30.00 - 34.99 Class I Obese 
35 - 39.99 Class II Obese 
≥ 40.00 Class III Obese 
   
“World Health Organization defines obesity as a BMI of 30 kg/m2 or 
greater, and overweight as a BMI between 25 kg/m2 and 29.9 kg/m2”(WHO,2002) 
[5] 
 
The Asian populations develop health consequences at a lower BMI, so it has been 
proposed that a BMI of 25 kg/m2 or greater should be classified as obesity (James 
et al, 2001).  
“Body fat percentage is the total weight of body fat divided by body 
weight”. A body fat percentage ≥ 23% in males and ≥ 29% in females indicates 
obesity. Body Fat Percentage (BF %) can be calculated from BMI in adults using 
the equation given below. 
BF% =   (0.23 x Age) + (1.2 x BMI) - (10.8 x Sex) - 5.4 
   Where, BMI is in Kg/m2; Sex=0 for female and 1 for male; Age is in yrs;  
Large scale epidemiologic studies suggest that cardiovascular and 
metabolic morbidities begin to rise when BMI is ≥ 25. The relative risks of death 
due to coronary disease for the increasing levels of BMI are given below showing 
that there is a proportionate increase in risk with the degree of obesity. 
Relative risk BMI 
1 < 19 
1 19 – 21.9 
1.4 22 – 24.9 
1.7 25 – 26.9 
3.1 27 - 28.9  
4.6 29 - 31.9  
5.8 >32 
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The Autonomic Nervous System (ANS) through its two divisions 
sympathetic and parasympathetic systems work in a coordinated manner either 
acting reciprocally or synergistically and regulate visceral functions. Autonomic 
imbalance with reduced vagal tone and increased sympathetic activity has been 
implicated in pathophysiology of arrhythmias and adverse cardiac events10,11,12.  
          A human heart in a healthy state does not beat at a regular rate. There occurs 
a variation from one beat to the next beat. Even under resting condition, the 
duration of cardiac cycle of all heart beats is not the same. This spontaneous 
variation is known as the Heart Rate Variability (HRV).  
Thus, Donald Moss and Fred Shaffer aptly described that “The human heart 
is a bio-electrical pump, beating at an ever changing rate; it is not like a clock that 
beats at a steady unchanging rate”. 
The heart rate is regulated by the autonomic nervous system and it is under 
the constant influence of external and internal stimuli. Metabolic and 
cardiovascular disorders are associated with autonomic dysfunction, leading to 
compromise in blood pressure and heart rate thus resulting in cardiovascular 
mortality.  
 In un-innervated human heart, the intrinsic firing rate of Sino Atrial Node 
(SA node) is 100 beats per minute (WJ Ganong) whereas in an innervated heart, 
the parasympathetic innervation supplied by vagus nerve, decreases the firing rate 
of SA node while the sympathetic system will increase the rate of depolarization 
of SA node. The net effect of the accelerating influences of the cardiac 
[7] 
 
sympathetic system and the decelerating influences of parasympathetic system 
will determine the cardiac sympathetic tone and parasympathetic tone 
correspondingly. The predominance of resting vagal tone over sympathetic tone is 
responsible for heart rate below 100.The heart rate (HR) is conventionally 
measured by counting the number of heart beats per minute. 
          R-R interval is the time interval between successive heartbeats which can 
be obtained from electrocardiogram (ECG) or plethysmogram. The sympathetic 
activity will decrease the RR interval and parasympathetic will increase the RR 
interval. 
The evaluation of autonomic disorders is available more widely with the 
advent of more reliable, non invasive techniques. The most commonly used 
autonomic function tests relies on heart rate and blood pressure and the changes in 
response to breathing and to posture variations. These tests are simple, non 
invasive tests, easy to perform and reproduce, and are both sensitive as well as 
specific. 
Greater heart rate variability implies that the heart adapts more quickly and 
flexibly to internal and external influences due to an optimum interplay between 
the PNS and SNS. Lower heart rate variability indicates a reduced ability for 
adaptation which in turn may suggest autonomic dysfunction leading to serious 
health impairment.  
[8] 
 
HRV is considered as an early tool that reflects distress. It is an early 
warning sign of alteration in homeostasis to evaluate the integrity and functional 
state of ANS. 
          The fact that autonomic innervation of SA node is responsible for 
variability of heart rate has been utilized to develop tests that stimulate this 
autonomic supply and produce variability of heart rate. These tests evaluate the 
cardiac division of the ANS, both sympathetic and parasympathetic system. They 
are grouped as cardiac autonomic functions tests. They test the autonomic reflex 
pathway, where the heart is the effectors end organ. The autonomic reflexes have 
an afferent pathway, a center that help in processing and   integrating and an 
efferent pathway like other reflexes. These tests assess the resting heart rate 
variability and its variability in response to a challenge. 
Task Force (1996) has designed and recommended a battery of tests to 
evaluate the autonomic functions13. The cardiovascular autonomic function tests 
includes orthostatic standing test, deep breathing test, isometric handgrip test, cold 
pressor test and resting heart rate variability.  
          Leptin was identified in 1994 by J.M.Friedman. Leptin is a 16 kDa protein, 
consisting of 167 amino acids 14 . It is produced by adipocytes under the 
neuroendocrine control 15 . In humans, the ''Ob''(Lep) gene is located on 
chromosome 7. Leptin functions as an anti-obesity hormone primarily. 
 
[9] 
 
By increasing overall sympathetic nerve activity, leptin reduces appetite, 
while it enhances energy expenditure 16 . It improves insulin sensitivity and 
facilitates glucose utilization. The circulating leptin level is considered to be in 
direct proportion to the total amount of body fat17. Insulin sensitivity may be 
affected by leptin either through direct peripheral effects in insulin-sensitive 
tissues or by centrally mediated mechanisms. Thus, leptin may regulate glucose 
metabolism with hypothalamus as center via central and/or peripheral pathways18.  
As such elevated plasma leptin levels may be an independent risk factor for 
the development of cardiovascular disease. Leptin that is considered a satiety 
factor thus increases energy expenditure by activating the sympathetic nervous 
system. There are also evidences which state that chronic infusion of leptin 
increases heart rate and blood pressure.  
 Therefore in this present study, the autonomic activity of young obese 
individuals are assessed by a battery of autonomic function tests, where obesity is 
a pro-inflammatory condition and also their serum leptin levels, which is a 
adipocytokine are assessed and compared and correlated with that of controls of 
normal BMI.  
 
 
 
 
 

[10] 
 
2. REVIEW OF LITERATURE 
Obesity has been known since human existence. Earlier it was considered 
as a symbol of prosperity. In ancient days, there was scarcity of food and adipose 
tissue remained as reserve of energy for utilization during the period of starvation. 
Some of the milestones in obesity are: 
 In Old Stone Age, obesity was depicted in many artefacts, of which ‘Venus 
of Willendorf’ found in Austria, showing a marked abdominal obesity and 
pendulous breast was the most famous one.  
 In New Stone Age, with the advent of agriculture and food security, many 
artefacts including ‘Mother Goddess’ found in Turkey depict obesity. 
 Hippocrates, a Greek physician said that “Corpulence is not only a disease 
itself, but the harbinger of others. Sudden death is more common in those 
who are naturally fat than in the lean.” Obesity as a cause of infrequent 
menstruation and infertility in women was also noted by Greek physicians.  
 Galen, a Roman physician distinguished between moderate and 
immoderate (morbid) forms of obesity.  
 
 “Obesity is characterized by excessive accumulation of fat in the body to an 
extent that it may have an adverse effect on health, leading to decreased 
expectancy of life and/or increased health problems” (WHO,2000) 19 . The 
definition of obesity is limited to BMI and to increases in adipocyte cell size 
and/or cell number (Bray GA et al, 1998)20. In 1985, in a Consensus Development 
[11] 
 
Conference on Health Implications of Obesity held by The National Institute of 
Health, obesity was concluded to be a disease.21  
 
Causes of Obesity: 
The common causes of obesity are positive energy balance and genetic 
susceptibility while a few cases are due to endocrine disorders, psychiatric illness, 
or medications. Modernization of lifestyle with physical inactivity, increased 
stress and easy availability of high caloric diet has probably lead to current level of 
epidemic of obesity. (James et al)22 
 
Classification of obesity:  
Obesity has been classified based on variety of features  
a) Anatomical distribution of fat: Peripheral obesity (pear shaped, gynoid, 
gluteo-femoral or lower body obesity) and Central obesity (apple shaped, 
android, abdominal or upper body obesity)  
b) Morphology of adipose tissue: Hyperplastic obesity (increased number of fat 
cells) and Hypertrophic obesity (enlarged fat cells) 
c) Period of onset: Juvenile, Mature or pregnancy related. 
 
Adipose tissue:  
Adipose tissue is of two type namely white or yellow adipose tissue, which 
forms the major part in human adipose tissue and brown adipose tissue (BAT) 
[12] 
 
which is present in significant amount in neonates to help in temperature 
regulation.   
 
Functions of adipose tissue: 
Energy storage and release of fatty acids when fuel is required was the 
traditional role attributed to white adipose tissue (Henry CJK et al, 1990) 23 . 
Adipose tissue is considered the body’s largest energy reservoir (Collins S et al, 
1995)24. It is basically required for glucose homeostasis to be normal.  
  Brown adipose tissue (BAT) is concerned with adaptive thermogenesis. In 
contrast to white adipose tissue, BAT expends stored energy as heat which it 
accomplishes through a unique mitochondrial protein namely thermogenin or 
uncoupling protein (UCP- 1) that uncouples fuel oxidation from ATP generation 
by breaking the hydrogen ion gradient across inner mitochondrial membrane.  
The metabolic role of white adipose tissue is complex and this tissue has 
multiple functions. It also acts as an endocrine organ. Siiteri PK et al in 1987 first 
suggested that adipose tissue may have endocrine function by identifying its 
ability to interconvert steroid hormones25.  
Adipose tissue normally acts as a whole as a single functional unit. It is 
identified that adipose tissue in different parts of the body may vary in their 
functions, the upper body subcutaneous tissue releasing major amount of systemic 
non esterified fatty acids (Martin ML et al, 1991)26 and also their proximity to the 
lymph nodes play a role (Pond CM et al, 1995)27.  
[13] 
 
Though the main function of adipose tissue is energy storage, other 
functions of synthesis and secretion of proteins that regulate various body 
functions are listed below.  
PROTEINS SECRETED BY ADIPOSE TISSUE ROLE 
Leptin 
Adenosine 
Acylation stimulating protein  
Friedman,Halaas et al28 
Kather et al29 
Sniderman et al30 
Regulation of fuel 
flux  
 
Adiponectin 
TNF-α  
Weyer et al31 
Moller et al32 
Regulation of 
insulin action  
Angiotensin converting enzyme 
Angiotensinogen  
PGI2  
Gorzelniak et al33  
Van Harmelen et al34 
Fink et al35 
Regulation of 
vasomotor tone 
TNF-β 
PGI2 
IGF-1 
Alessi et al36 
Negrel et al37 
Wabitsch et al38  
Regulation of cell 
turn over  
Interleukin – 6 
Adipsin  
TNF – α 
Hirano et al39 
Esterbauer et al40 
McDermott et al41 
Regulation of 
inflammation 
17 β – OH steroid 
Cytochrome P 450 dependent 
aromatase 
Crobould et al42 
Bulun et al43 
Steroid conversion, 
reproduction, bone 
mass 
Plasminogen activator inhibitor-1 
PGI2 
Crandall et al44 
McCarty et al45 
Regulation of 
coagulation 
Agouti signal protein Voisey et al46 Others 
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Adipocytokines:  
Adipose tissues produce a wide range of proteins termed Adipocytokines. 
Adipocytokines highlight that these proteins may also act locally in an autocrine 
and paracrine fashion in addition to acting on distant organs in an endocrine 
fashion. Adipose tissue can thus regulate its own function through adipocytokines. 
 
Regulation of fatty deposits : 
Functions of adipose tissue are regulated by various factors such as rate of 
blood flow, autonomic nervous system activity and the delivery of hormones and 
substrates in the plasma. The metabolism in adipose tissue is complex and 
dynamic. The triacylglycerol (TG) stored in adipocytes depicts the net balance 
between fat deposition and mobilization.  
 
Blood supply of adipose tissue: 
It is around 3ml/100gms/min after an overnight fast47. The blood flow is 
highly labile. It increases in response to a meal, prolonged exercise, prolonged 
fasting.  
Expanding fat stores in obesity requires new blood vessels for blood 
supply. Angiogenesis, a process of new blood vessel formation, occurring in 
adipose tissue appears to be regulated by factors secreted by the adipose tissue 
itself like Leptin which has angiogenic properties48 and matrix metaloproteinases 
which are involved in vascular remodeling49.  
[15] 
 
The adipose tissue releases non esterified fatty acid (NEFA) into the 
circulation. This transport needs a supply of albumin and thus an increased 
substrate delivery for clearance of triacylglycerol.  
 
Innervation of adipose tissue: 
ANS innervates white adipose by, both sympathetic which control catabolic 
processes and parasympathetic divisions which control anabolic processes 
(Bartness T J et al, 1989) 50 . The sympathetic nervous system (SNS) releases 
neurotransmitter noradrenaline. The catecholamines, adrenaline and NA and the 
antagonist or agonists of the adrenoceptors can influence the blood flow to the 
adipose tissue. Alterations in number and subtypes of adrenoceptor occur in 
obesity (Lafontan M et al, 1995)51. Energy stores and adipocyte size modulate the 
autonomic signals to adipose tissue. Parasympathetic innervation of adipose tissue 
when stimulated decreases lipolysis (Kreier F et al, 2002)52.   
 
Fat deposition: 
 The de novo lipogenesis in human fatty tissue is less (Shrago et al)53 and 
insiginificant except when there is overfeeding (Hellerstein et al, 1996)54. Insulin 
stimulates both adipose tissue lipoprotein lipase activity and esterification, leading 
to dietary TG storage in the postprandial period. Increase in vascularity of adipose 
tissue during postprandial period may be involved in this TG storage in the 
adipose tissue.  
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Steroid hormones like sex steroids and glucocorticoids may regulate the fat 
storage in specific sites.  
Acylation-stimulating protein (ASP), a peptide containing 76 aminoacids, is 
also found to stimulate fat deposition by stimulating esterification of fatty acid in 
adipose tissue.  The presence of chylomicrons in vitro stimulates the production of 
acylation stimulating protein.  
 
Fat mobilization: 
Activation of hormone-sensitive lipase stimulates fat mobilization pathway. 
Increased gene transcription may also be involved.  
Insulin suppresses the pathway of fat mobilization leading to suppression of 
release of non esterified fatty acids from subcutaneous adipose tissue. 
Catecholamines activate lipolysis, via β-adrenergic receptors. Growth 
hormone and cortisol also modulates fat mobilization. It has been suggested that 
Atrial natriuretic peptide (ANP) also activates HSL. 
 
Differentiation of adipose tissue:  
 Preadipocytes can differentiate into mature adipocytes throughout life 
(Hauner H et al, 1989)55. Insulin and fatty acids are important signals for such 
differentiation. Fatty acids act via PPARγ and PPARδ of the peroxisome 
proliferator-activated receptor family56 . Probably a fatty acid derivative is the 
natural ligand for PPAR (Forman BM et al, 1995)57. 
[17] 
 
Insulin regulates adipose tissue differentiation through sterol regulatory 
element binding protein-1c58. Adipocytes in different stages of development may 
vary in adipocytokine production. The production of TNF-α is less in 
preadipocytes than in mature cells.  
 
Obesity as an inflammatory disease: 
White fat also plays a role in inflammatory processes. Adipsin (Esterbauer 
et al, 1999), Interleukin – 6 (Hirano et al, 2000), TNF – α (McDermott et al, 2001) 
secreted by adipocytes play a great role in inflammation and hence obesity is 
considered a pro-inflammatory condition. Obesity is identified to be a low grade 
chronic inflammatory disease associated with infiltration of macrophages and 
expression of high levels of inflammatory markers.  
Yamaguchi et al, 2005 has stated that these inflammatory markers 
contribute to systemic inflammation. The number of macrophages infiltrating the 
adipose tissue has a strong correlation with body mass index, total body fat, body 
weight (Weisberg et al, 2003).  
In obesity the enlarging mass of adipose tissue results in hypoxia well 
before the occurrence of angiogenesis. This hypoxia leads to recruitment of a 
transcription factor namely hypoxia-inducible factor-1 (HIF-1) (Trayhurn et al, 
2004). HIF-1 acts as a chemotactic agent and induces infiltration with 
inflammatory cell especially macrophages and results in local as well as systemic 
inflammation. 
[18] 
 
 
    
Figure- 1. Pathogenesis of inflammation in obesity 
 
The inflammatory cytokines released from the adipocyte as a result of 
inflammation namely adipokines are of more than 50 different types like tumour 
necrosing factor- α (TNF-α), many interleukins and inflammation-related signals 
such as Monocyte chemo attractant protein-1 (MCP-1), Macrophage migration 
inhibiting factor (MIF), nerve growth factor, and adiponectin which are different 
in structure and of function.  
Out of these adipokines, the rate of secretion and plasma levels of MIF, its 
mRNA and MCP-1 positively correlated with BMI (Sartipy and Loskutoff et al, 
2003, Skurk et al, 2005). Thus “MIF and MCP-1 may be considered as key 
obesity-dependent mediator of macrophage infiltration of adipose tissue”. 
[19] 
 
Circulating levels of IL-6, C-reactive protein, TNFα and its soluble receptors, IL-
18 and acute phase reactants like plasminogen activator inhibitor-1 and 
haptoglobin, Amyloid A are also increased in obesity. These evidences support the 
basis that the obesity is characterized by chronic low grade inflammation in 
adipose tissue associated with obesity. 
 
Obesity associated inflammation induces oxidative stress: 
            In obesity, oxidative stress markers derived from oxidation of low-density 
lipoprotein like lipid peroxides, 8-hydroxydeoxyguanosine and nitrative stress 
markers like 3-nitrotyrosine and 3-chlorotyrosine are elevated along with high-
sensitivity C-reactive protein (hsCRP), which is an early indicator of inflammation 
(Ignazio et al, 2007). Major source of increased oxidative stress in obesity is 
NADPH oxidase. 
There occurs an imbalance between the production of free radicals 
particularly high levels of reactive oxygen species and their scavenging 
mechanism that is low antioxidant enzyme protein content like manganese, 
copper, zinc super oxide dismutase and catalase which results in disturbances of 
cellular redox homeostasis (Shattock et al, 1995). 
             Hence, the excess production of oxygen free radicals in obesity causes 
injury to deoxyribonucleic acid (DNA), lipid membranes, proteins, and other 
cellular components. Peter Viitala et al., (2008) reported that the free radical 
damage to lipid membrane results in lipid peroxidation. “Lipid peroxidation is 
[20] 
 
defined as the oxidative deterioration of polyunsaturated fats in cellular lipid 
membranes caused by oxygen free radicals and its propagation”.  
 
Net effect of inflammation and oxidative stress on obese individuals: 
The oxidative stress, inflammation and nitrative stress increased in obesity 
contributes to the pathogenesis of Metabolic syndrome which includes diabetes 
mellitus, hypertension, hyperlipidemia and obesity (Yu Yamaguchi et al., 2005) 
and various above mentioned associated co morbid conditions like aging, 
Alzheimer's disease, kidney disease, neurodegenerative disorders and cancers 
(Peter and Keaney et al, 2003).  
 
 
Obesity- Changes in Cardiovascular functions:  
A variety of cardiovascular changes from a hyperdynamic circulation to 
overt heart failure may occur in obesity 59 . Obesity is associated with 
haemodynamic overload 60 . The increased metabolic demand imposed by the 
expanded adipose tissue and augmented fat-free mass in obesity results in a 
hyperdynamic circulation with increased blood volume leading to the increased 
preload. 
 In addition left ventricular afterload shows a raise in obesity because of 
increase in peripheral resistance and arterial stiffness61. Right ventricular afterload 
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may be elevated, possibly due to associated sleep apnea and left ventricular 
alterations62. 
 Cardiac output is raised in obesity, due to raise in stroke volume and heart 
rate due to increased sympathetic outflow.  Intolerence to exercise occurs in 
obesity, as their ejection fraction do not accentuate with exercise63. The increased 
resting left ventricular end diastolic volume in obesity has been interpreted as 
evidence of enhanced recruitment of preload reserve based on Frank-Starling 
mechanism.  
Obesity adversely impacts cardiac diastolic function. Elevated systemic 
oxidative stress and renal sodium retention happening in obesity (Keaney JF et al, 
2003)64 and proinflammatory cytokines from adipocytes (Lyon CJ et al, 2003)65 
may be involved in pathogenesis of left ventricular dysfunction. A straight 
lipotoxic effect on heart too occurs (Chiu HC et al, 2001)66.  
Atrial and ventricular remodeling, aggravated by hypertension, which are 
considered to lead to atrial and ventricular dysfunction respectively occur in 
obesity. Obese individuals have larger left atrium is enlarged, due to increased 
intravascular volume and changes in LV filling.  Obesity is associated with 
eccentric (being more common) and concentric types of left ventricular 
hypertrophy (Lauer MS et al, 1992) 67 . Thus obesity is associated with 
cardiomyopathy.  
 
 
[22] 
 
Autonomic Nervous system (ANS): 
The term autonomic nervous system was coined by Langely in 1898 to 
describe that part of nervous system which controls the automatic, unconscious 
functions. ANS is an involuntary system and as it controls the vegetative functions 
it is also called as vegetative system. The autonomic nervous system is responsible 
for the motor control of the viscera hence called the visceral motor system. 
  The visceral afferent fibers originate from sensory receptors in the viscera 
carrying sensations like hunger, thirst, nausea, pain and a sense of visceral 
distention. Whenever internal stimuli signals about derangement of the internal 
environment, its autonomic nerves and the central nervous system (CNS) 
commands compensatory actions. Thus the ANS collects the information about the 
changes that takes place in the internal environment, interprets these changes and 
guides the actions and gets the plan executed with the help of effector organs of 
ANS like smooth muscles of viscera, cardiac muscles and secretory epithelium of 
glandular tissues. The autonomic nervous system assists the body in maintaining 
the constancy of internal environment (homeostasis).   
 
Divisions of ANS: 
The autonomic nervous system is further divided into sympathetic nervous 
system (SNS) and parasympathetic nervous system (PNS), each having a central 
and peripheral component.  
[23] 
 
The sympathetic preganglionic neurons are situated in the intermedio-
lateral horn of thoracic and upper lumbar segments (T1 to L2) of the spinal cord 
hence the name thoraco-lumbar division. The parasympathetic preganglionic 
neurons are found in the brainstem and in the intermediolateral grey horn of sacral 
spinal cord (S2 to S4) hence the name craniosacral division. Their axons leave 
the central nervous system and they synapse in specialized ganglia.  
Sympathetic postganglionic neurons are located either in paravertebral or 
prevertebral ganglia. Parasympathetic postganglionic neurons are located in 
ganglia, which lie close to or within the walls of the target organs. Postganglionic 
neurons (Second order neurons) innervate smooth muscle and cardiac muscle 
directly. 
 
Higher centers of ANS: 
Higher centers reside in brainstem, limbic system and hypothalamus. Since 
hypothalamus plays a vital role in the regulation of autonomic activity, it has been 
called the main ganglion of the ANS. Higher centers have vital connections with 
the preganglionic neurons to integrate and regulate visceral functions in order to 
maintain homeostasis.  
        Most of the viscera have both sympathetic and parasympathetic innervations. 
The sympathetic and parasympathetic nervous systems of the organs  work in a 
highly coordinated manner, sometimes acting reciprocally and at times 
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synergistically to regulate visceral functions in order to maintain the internal 
environment.(Berne and Levy,6th edition)68 
 
Neurotransmitters in ANS: 
Acetylcholine is the primary neurotransmitter in both pre ganglionic and 
postganglionic neurons of the parasympathetic system. Nor epinephrine is the 
primary neurotransmitter in sympathetic end organ targets with two main subtypes 
of alpha and beta receptors. Otto Loewi in 1920 provided the first evidence for 
chemical neurotransmission by performing a simple yet dramatic study of heart 
rate control by the parasympathetic nervous system. (Ganong, 23rd edition)69  
 
Cardiovascular autonomic nervous system:  
Both sympathetic and parasympathetic nerves innervate the heart and the 
vascular system. ANS of the heart is under the control of cardiac autonomic 
centers situated in the medulla, which integrates the cardiac autonomic reflex. 
Vasomotor center is the primary cardiovascular regulatory center located in the 
medulla oblongata of brainstem.  
The sympathetic supply is controlled by cardiac excitatory area (Pressor 
Area) in Rostral Ventero Lateral Medulla (RVLM). The cervical sympathetic 
nerves reach the heart, thus forming the efferent limb of cardiac autonomic 
reflexes. The parasympathetic center is located in nucleus ambiguous and dorsal 
motor nucleus of vagus and its output reaches the heart through the vagus nerve.  
[25] 
 
Afferent inputs from various central and peripheral organs also reach these 
cardiac autonomic centers. Some of the inputs excite the cardiac sympathetic 
centers, which in turn inhibit the parasympathetic centre. Thus there is an 
antagonist effect of these vital centers on each other. 
           
 Figure -2. Autonomic innervation of heart. 
 
 Heart is innervated by both divisions of autonomic nervous system namely 
sympathetic and parasympathetic nerves. Sympathetic preganglionic fibers 
originating in the intermediate horns of upper 4 or 5 thoracic spinal segments relay 
in stellate ganglion, then reach the heart and innervate the pacemaker, the 
conducting system, atrial and ventricular muscles. The vagus nerve 
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(parasympathetic) originates from the dorsal nucleus of vagus in medulla, then 
ends in ganglia close to sinoatrial and AV node and the post ganglionic nerves 
which are short and supply the pacemaker, the conducting fibers, and also sparsely 
innervates the muscle fibers. 
The vagus innervates the SA node (the pacemaker) by its right branch, AV 
node by its left branch and the conducting system of heart. Heart has its own 
inherent activity which is visualized as spontaneous firing of pacemaker cells 
situated in the wall of right atrium. These pacemaker cells of SA node are 
specialized cardiac muscle cells with large number of gap junctions and scanty 
contractile fibers. Many local factors such as changes in the hormone, temperature 
and stretch of the SA node change the heart rate. Above all, a vital role is played 
by ANS in controlling heart rate effectively.  
On stimulation, vagus releases acetylcholine from the post ganglionic 
nerves which makes the cardiac fibers less excitable. The acetylcholine increases 
the potassium permeability leading to increased potassium efflux resulting in 
hyper polarization of the membrane, the end result being reduced excitablility of 
the tissue. Vagal stimulation leads to reduction in the rate of pacemaker impulses, 
slowing of conduction in the conducting system, reduction in the force of 
contraction of atrial muscles and the ventricle muscle is least affected and thus 
vagus is cardio inhibitory. 
The impulses from the cardio respiratory region of medulla reach the heart 
through the vagus and keep a check of heart rate which is called as vagal tone. The 
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vagal tone originates from the sinoaortic baroreceptors, the impulses then reach 
medullary cardio inhibitory center and send impulses to heart through vagus. 
Denervation of the SA node causes abolition of vagal tone. 
 The sympathetic stimulation is chronotrophic (increases the heart rate), 
inotropic (increases the force of contraction), dromotropic (increases the 
conduction velocity) and bathmotrophic (increases the excitability). Sympathetic 
stimulation releases Noradrenaline from the post ganglionic nerve terminals which 
causes a reduction in potassium efflux and opens the transient calcium channels in 
SA node. The opening of L type of calcium channels in the cardiac muscles 
increase the force of contraction. These actions are mediated by β1 receptors in the 
cardiac tissue. (Frielle T et al)70. 
There is some degree of sympathetic tone along with vagal tone and 
sympathetic denervation reduces the heart rate considerably. Sympathetic tone 
also maintains the vessels in partially constricted state thus maintaining the 
vascular resistance and playing a vital role in the maintenance of the blood 
pressure.  
Normally there exists a balance between sympathetic and parasympathetic 
tone and called as sympathovagal balance. In a denervated heart, where both 
sympathetic and parasympathetic nerves are blocked, the heart beats at the rate of 
100 -110 beats/ minute which is called as the intrinsic heart rate. But the normal 
adult resting heart rate is around 72 beats / minute which suggest that under resting 
conditions the parasympathetic tone predominates. 
[28] 
 
Autonomic Function Testing: 
Rather than relying on a single test, it is preferable to perform a battery of 
tests to determine the intactness of autonomic reflex (Ewing and Clarke et al, 
1982)71 
The cardiovascular autonomic function tests that relies on blood pressure 
and heart rate and the changes in response to breathing, and to postural variations 
are frequently used for testing the integrity of autonomic nervous system and 
thereby the regulation of homeostasis (Genovelyland et al, 1998)72. The fact that 
variability of heart rate occurs because of autonomic innervations of SA node has 
been exploited to develop tests that stimulate this autonomic supply and produce 
variability of heart rate.  
These tests which are simple, easy to perform and reproduce, non invasive, 
sensitive as well as specific are listed below: 
 
Non invasive tests of Autonomic Function:  
These tests were adapted from Text book of clinical evaluation of 
diagnostic test for NM disorders. (Annabel K. Wang) 
 
Tests for Sympathetic nervous system: 
 Heart rate and BP response to active standing 
 Beat to Beat Blood pressure response to Valsalva maneuver  
[29] 
 
 BP and HR response during and after 5 minutes of isometric hand grip test  
 Diastolic BP and heart rate response during cold pressor test 
 
Tests for Parasympathetic nervous system: 
 Response of heart rate (HR) to standing  
 Response of HR to deep breathing 
 Heart rate response to Valsalva maneuver  
 
Orthostatic Standing Test (OST) 
The heart rate during initial 30 seconds after active standing from supine 
position is measured. Continuous heart rate recording demonstrate that the heart 
rate peaks at 15th beat, starts slowing at 20th second reaching a minimum at 30th 
beat.  
When the subject assumes the erect posture from supine position, pooling 
of blood towards the lower limbs occurs due to gravity causing a decreased venous 
return which in turn reduces the cardiac output and arterial pressure that is sensed 
by the arterial baroreceptors which results in baroreceptor unloading and a 
consequent vagal withdrawal producing an instantaneous increase in heart rate, 
which peaks around 15th beat after which the blood pressure returns to normal 
level resulting from baroreceptor mediated slowing of heart rate, which is evident 
around the 30th beat (Borst et al 1982)73.  
[30] 
 
This test provides an estimate of the cardiac parasympathetic control as the 
changes in heart rate are largely mediated by parasympathetic withdrawal and 
activation reflecting the changes in baroreceptor afferent traffic.  
 
Deep Breathing Test (DBT) 
Heart rate variability during respiration which is known as sinus arrhythmia 
results from the influence of afferent vagus on the medulla by reflex feedback 
loops, mediated by stretch receptors located in the lungs, chest wall, heart, blood 
vessels and by the respiratory centers.  
It decreases with age and increases at slower respiratory rate at around 5-6 
respiration/min. The changes in the baroreceptor responsiveness during different 
phases of ventilatory cycle provide additional modulation of heart rate. 
The impulses from the stretch receptors in the lungs during inspiration 
cause vagal inhibition and the increased venous return due to fall in intrathoracic 
pressure causes the stimulation of arterial stretch receptors, which produce vagal 
inhibition and further spill over of impulses from respiratory center into the 
adjacent vagal motor neurons causes their inhibition leading to tachycardia. 
Conversely, expiration decreases the venous return and heart rate slows. After 
cooling of the vagus nerve or by atropinization it is documented that the reflex 
response is abolished (Fouad et al, 1984)74  
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Valsalva maneuver: 
This procedure evaluates the function of the baroreceptors. This test is done 
by a forced voluntary expiration of a subject against resistance. It consists of four 
phases. Phase I- raise in transthoracic pressure, transient elevation in blood 
pressure and decrease in heart rate. Phase II- Reduced venous return resulting in 
low stroke volume, ultimately ends in reduced blood pressure and compensatory 
raise in heart rate. Phase III- End of expiration resulting in further reduced blood 
pressure due to pulmonary vascular expansion and heart rate increases. Phase IV–
Baroreceptor activation, abrupt raise in blood pressure and bradycardia. 
 Fall of BP at the beginning of phase II should not exceed 21 mmHg and at 
the end of phase II or in phase III it should return to baseline values (Agnieszka 
Zygmunt et al, 2009) 
“Valsalva Ratio (VR) is derived from the longest RR interval in phase IV 
divided by the shortest RR interval in phase II and at the very beginning of phase 
III”. VR <1.21 is considered abnormal. Valsalva ratio reflects parasympathetic 
activity, whereas variations in blood pressure are a measure of sympathetic 
function.  
 
Isometric Handgrip Test (IHG) 
Sustained muscle contraction causes increased blood pressure and heart rate 
as a result of exercise reflex, which increases the sympathetic and reduce the 
parasympathetic activity. The heart rate changes by parasympathetic cholinergic 
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function and blood pressure changes are regulated by sympathetic adrenergic 
function. (Textbook of Clinical neurophysiology, Misra 2nd edition)75  
 
Cold Pressor Test (CPT) 
Immersion of hand or foot in ice cold water causes motor reflex activation, 
leading to elevation in blood pressure and cardiac output, stimulated by cutaneous 
pain receptors. Raise in vascular resistance leads to elevation of blood pressure 
due to enhanced sympathetic activity (Victor et al, 1987)76 
 
Resting Heart Rate Variability test: 
Studies in last 30 years have shown a great significance between autonomic 
nervous system and cardiovascular morbidity, including sudden death in 
arrhythmias (Levy et al, 1994)77.   
The duration of cardiac cycle of all heart beats occurring in one minute, 
even under resting condition is not the same. There is spontaneous beat to beat 
variability of RR interval in milliseconds which is known as Heart rate Variability 
(HRV). The reason for normal fluctuation of heart rate is respiratory arrhythmia, 
baroreceptor reflex, circadian rhythm and thermoregulation.  
Hon and Lee in 196578 recognized that, alterations in HRV preceded before 
any notable changes occurred in heart rate as such in cases of foetal distress.  
In 1985, Ewing et al79 introduced simple test for short term study of RR 
difference to detect diabetic neuropathy  
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 In 1981, Akselrod et al80 introduced first power spectral analysis of heart 
rate fluctuation for quantitative evaluation. 
The higher the HRV, the quicker and more flexibly the heart adapts to 
external and internal influences and the better the organism react to the 
environment. Higher heart rate variability reflects optimal cooperation between 
sympathetic and parasympathetic nervous system. 
 Depressed HRV means depressed activity of the autonomic regulatory 
function and the ability to maintain the homeostasis. It primarily means that heart 
rate is monotonously regular. A low HRV, indicates a reduced capacity for 
adaptation and may suggest serious health impairment (Sampler MB et al, Lele AS 
et al, 1980) 
HRV changes might be a first sign of distress, reflecting involvement of 
more energy dependent sympathetic system. The decrease in biological signals 
variability is a warning sign of a homeokinetic self regulation loss. HRV can 
reflect changes in body stress, while other physiological parameters are still in 
"normal" accepted ranges.  
 Heart rate variability (HRV) is a measure of the respiratory sinus 
arrhythmia. Normally the heart rate accelerates during inspiration, and decelerates 
during expiration. This normal phenomenon decreases with age and also under 
stressful conditions. Human studies on blocking the parasympathetic system using 
atropine (Berntson et al, 1994) indicate that HRV is a function of parasympathetic 
activity. 
[34] 
 
  
Figure- 3. Sinus arrhythmia 
 
The resting Heart rate variability is one of the non invasive tests to evaluate 
the integrity and functional state of ANS. Animal studies have shown that HRV is 
considered a marker of vagal activity (Brouha and Nowak, 1939).  
It was proposed that the heart rate variability is a non invasive cardio 
graphic marker reflecting the activity of sympathetic and vagal component of ANS 
on sinus node of the heart (Stein P.K et al, 1994) 
In 2004, Juan Sztajzel et al, stated that “heart rate variability has emerged 
as a simple non-invasive method to evaluate sympathovagal balance at the 
sinoatrial node among the different available noninvasive techniques for assessing 
autonomic status”81. 
HRV analysis being highly complex, “European society of cardiology and 
North American society of pacing and electrophysiology” have contributed a Task 
Force for developing appropriate standards. The guide lines and recommendations 
of Task Force, 1996 82are followed in this study. 
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Measurement of HRV: 
In this review the term HRV actually means the variability of RR intervals 
which is the interval between consecutive R peaks. In 1983, Persson et al 83 
computed that the RR interval variation (RRIV), as a measure of the heart rate 
variability and one of the simplest and reliable test used for the evaluation of the 
autonomic functions of the heart. 
In HRV analysis either the heart rate as a function of time or the intervals 
between successive QRS complexes need to be determined. Using the ECG signal 
it is possible to detect the regular pattern of beats using specially designed 
software algorithms. Such an algorithm is able to process the recording signal and 
determine with some precision when each beat is occurring. 
 
    Figure -4. RR interval 
 
Analysis of HRV:  
Two broad categories of measures to standardize physiological and clinical 
studies were defined by the Task force, 1996. 
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 Time domain methods 
 Frequency domain methods 
HRV can be assessed either for a short term of 5 minutes or for a long term 
of 24 hours recording. Frequency domain methods should be preferred for short 
term recording and Time domain methods are preferred for long term recording 
(Task force, 1996).  
 
Time domain methods: 
Time domain measures are the simplest to calculate. By a continuous ECG 
record the heart rate at any given point in time and the interval between successive 
normal complexes is determined. Each QRS complex is detected and the so called 
NN interval that is all intervals between adjacent QRS complex resulting from 
sinus node depolarization or the instantaneous heart rate is determined. Time 
domain measures include the mean normal- to- normal (NN) intervals during the 
entire recording and statistical measures of the variance between NN intervals. In 
practice, RR and NN intervals usually appear to be same (Task force, 1996). 
The majority of time domain metrics are statistical methods. It should be 
calculated over a specific and fixed period of time, or epoch, either short term for 
5 minutes or long term for 24 hours to carry any significance.  
The SDNN is the standard deviation of these Normal to Normal intervals 
which are simple variable and expressed in milliseconds. This is equal to square of 
variance which is equal to total power of variance. Significant results are achieved 
[37] 
 
only by comparing SDNN values which may be unreliable if they are calculated 
over too short epochs. SDNN reflects the variability in the period of recordings. 
As SDNN gets reduced HRV gets reduced. 
 Mean HR is the Mean of the selected RR interval and Mean RR is the 
Mean of the selected RR series. 
 
Frequency Domain Methods:  
Power spectral density (PSD) analyzer gives the fundamental information’s 
of how the power (variance) distributes as a function of frequency. By proper 
mathematical algorithms, an estimate of true power spectral density can be 
obtained. The commonly employed methods are 
 Non parametric methods 
 Parametric methods 
In non parametric method, Fast Fourier Transform (FFT) is used as 
algorithm. This is very simple and has a high processing speed. The Power 
Spectral Component has recordings ranging from 4-400 MHz. The result is shown 
on a power spectrum, which shows a breakdown of all the frequencies 
(oscillations) contained in each epoch. The spectrum is calculated over the same 
epoch duration as the SDNN metric (long or short term) and the relative power or 
total power for selected sub-bands of the whole spectrum is computed.  
Frequency domain Power spectral density (PSD) analysis provides the 
basic information of how power distributes as a function of frequency. The PSD is 
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analyzed by calculating powers and peak frequencies for different frequency 
bands. The three main components that are distinguished in a spectral calculation 
for short term ECG recording are: 
Components Frequency range 
Very low frequency VLF 0‐0.04Hz 
Low frequency LF 0.04‐0.15 Hz 
High frequency HF  0.15‐0.4 Hz 
 
High frequency power (HF, 0.15-0.4Hz): 
                 This power spectral oscillation is seen only for parasympathetic   
nervous system. HF power is mostly influenced by processes modulating gas 
exchange efficiency, respiratory sinus arrhythmia (RSA) and activity from the 
Vagus nerve. This is specially blocked by parasympatholytic drugs. Even 1 minute 
ECG recording is enough 
 
Low frequency power (LF, 0.04-0.15Hz): 
This is an indicator for more sympathetic than parasympathetic modulation.  LF 
frequencies show activity of the baroreflex function which maintains blood 
pressure and of the sympathetic system. This needs minimum of 2 minutes ECG 
recording. 
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Very low frequency power (VLF, 0-0.04Hz): 
The physiological explanation of the VLF component is much less defined 
and the existence of a specific physiological process attributable to these heart 
period changes might even be questioned. It is not much relevant in short term (5 
minutes) ECG recordings. 
 
Normalization of units: 
LF (n.u) and HF (n.u) are the normalization of the powers which gives near 
100% values of the sympathetic and parsympathetic events. They are calculated as 
follows: 
LF (n.u) = LF power/(LF + HF power) or LF power / TP-VLF 
HF ( n.u) = HF power/ (LF+HF power) or HF power / TP-VLF 
Total power = LF+HF power 
 
LF/HF ratio: 
  This has been used as a index of global sympatho-vagal balance. 
Measurement of LF, HF is made in normalized units (Mallinai A et al, 1991)84. 
The distribution of LF and HF are not fixed but vary in relation to changes in the 
autonomic modulation of heart period. 
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Clinical Uses of HRV: 
  HRV is the non‐invasive simple test for measuring both cardiovascular and 
non cardiovascular autonomic function. HRV analysis is a predictor of risk for 
myocardial infarction, arrhythmias  and diabetic autonomic neuropathy.  
HRV analysis is used to find out the functional disorders earlier. It is used 
to evaluate the effectiveness of treatment and prognosis and to confirm the effect 
of stress relaxation program (meditation, massage, light therapy, exercise). HRV is 
used for exercise training in sports physiology 
 
Leptin: 
Leptin, is one of the most important adipocytokine produced by the 
adipocytes and is considered to be an appetite suppressor peptide (satiety factor) 
named “leptin” after the Greek word “leptos” for thin. It is a 16 kDa protein 
product of Ob gene consisting of 167 amino acids. It was originally discovered by 
JM Friedman through positional cloning of ob/ob mice, a mouse model of obesity 
found at Jackson Laboratories. Since then it is one of the most important central 
and peripheral signals for the maintenance of energy homeostasis (Friedman JM et 
al, 1998)85.  
The ''Ob (Lep)'' gene, is located on chromosome 7 in humans, Ob stands for 
obese, Lep for leptin. Specific leptin receptors (Ob-R) are expressed in the brain as 
well as in peripheral tissues. Ob/ob mice, which lack leptin and db/db mice which 
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lack leptin receptors are obese. Human beings with a homozygous mutation in the 
leptin gene or the leptin receptor have morbid obesity. 
 
Mechanism of action of Leptin: 
Leptin Receptors (Ob-Rs): 
There are six isoforms of leptin receptors namely Ob-Ra, Ob-Rb, Ob-Rc, 
Ob-Rd, Ob-Re and Ob-Rf, and are closely related to Class I cytokine receptor 
family. Ob-Ra and Ob-Rb represent the dominant isoforms in the heart while the 
other receptors are expressed at low levels (Fei H et al, 1997) 86 . The Ob-Ra 
isoform which is short leptin receptor isoform, plays an important role in 
transporting leptin across the blood–brain barrier. ObRb isoform which are the 
long leptin receptor isoform are present in ‘the hypothalamus, an important site for 
the regulation of energy homeostasis and neuroendocrine function’ and mediate 
signal transduction. Ob-Re is the secreted form that binds circulating leptin, 
regulating the concentration of free leptin87.  
 
Leptin signaling: 
It is observed that Ob-Rs activate mitogen-activated protein kinase 
(MAPK) pathways, Janus-activated kinase (JAK), insulin receptor substrate, 
signal transducers and activators of transcription (STAT), of which the most 
predominant is the JAK/STAT pathway (Vaisse and Halaas et al, 1996)88. Leptin 
receptors on ligand binding undergo homooligomerization (Nakashima K et al, 
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1997)89. Then it binds with Janus Kinase JAK2 primarily (Kloek Cet al, 2002)90. 
This leads to JAK2 autophosphorylation and phosphorylation of tyrosine kinases 
involved in intracellular cytokine signaling. Binding of members of Suppressors of 
cytokines signaling family (SOCS3) to tyrosine or receptor janus kinase complex 
mediates negative feedback on leptin signaling (Dunn SL et al, 2005)91. Only Ob-
Rb contains STAT-binding site (Bjorbeck C et al)92. 
 The long-form leptin receptor (Ob-Rb) signaling through JAK2/STAT3 is 
required for control of feeding and energy expenditure to maintain normal energy 
homeostasis. Mutations of this gene result in the obese phenotype of the db/db 
mouse and the Zucker rat (Zhang Yet al, 1994)93. The soluble leptin receptor 
isoform Ob-Re may oppose leptin transport by decreasing surface binding and 
endocytosis of leptin(Bates SH et al, 2003)94 
 
 
Figure- 5  Leptin signaling pathway 
[43] 
 
 
Disruption of leptin signaling in the hypothalamus leads to obesity and 
confirms the central role of leptin in the maintenance of energy balance (Cohen P 
et al, 2001)95. In addition to its action on CNS, through its peripheral receptors 
affect many systemic processes, such as immunity (Lord GM et al, 1998) 96 , 
reproduction (Margetic S et al, 2002)97, and cardiovascular functions (Rahmouni J 
and Haynes WJ et al)98. 
 Leptin secretion is pulsatile with a prominent diurnal variation with higher 
levels in early morning and evening. Circulating leptin levels correlates with the 
amount of energy stored in fat and changes in caloric intake (Licinio J et al, 
1998)99. Women have greater leptin concentrations than men. Leptin concentration 
in women is higher in the luteal phase of the menstrual cycle (Ludwig M et al, 
2000)  
 
Leptin Resistance or Tolerance: 
Hyperleptinemia is seen in many genetic variants including the Lys109Arg 
or Gln223Arg mutation in the leptin receptor (LEPR) gene. Mutations of some 
other genes including Pro-opio melanocortin (POMC) and the melanocortin 4 
receptor (MC4R) also result in an obese phenotype with associated 
neuroendocrine dysfunction. 
[44] 
 
 In obesity Leptin transport across the blood-brain barrier is impaired. This 
is partially due to saturation of the transporter as a result of hyperleptinemia and a 
subsequent decrease in transport activity (Van Rossum C et al 2003). 
 Endoplasmic reticulum stress is one of the proposed causation for 
development of leptin resistance. Humans and animals with obesity and diabetes 
have elevated endoplasmic reticulum stress in adipose tissue, liver and pancreatic 
cells which decreases signaling of leptin receptors in hypothalamus. (Sharma NK 
et al 2008). 
  
Role of Leptin in Food Intake and Energy Homeostasis: 
Leptin plays a significant role in maintenance of energy homeostasis, 
metabolism, and neuroendocrine function. Level of circulating leptin is 
proportional to amount of adipose tissue store. It is an indicator for energy 
reserves and directs the central nervous system to adjust food intake and energy 
expenditure accordingly.  
Leptin acts immediately on the brain especially hypothalamus to regulate 
appétite via ObRb-receptor binding activateing a complex neural circuit via 
melanocortin pathway comprising of anorexigenic and orexigenic neuropeptides to 
control food intake (Kelesidis et al). Arcuate nucleus in the hypothalamus sends 
output to Lateral nucleus which is the feeding centre, and Ventromedial centre 
which is the satiety centre. 
[45] 
 
 Arcuate nucleus contains two types of neurons of which the first group co-
expresses Neuropeptide Y (NPY) and Agouti related Peptide (AgRP) which are 
orexigenic neuropeptides that is stimulatory to feeding centre and inhibitory to 
satiety centre. The other group co-expresses POMC (Pro-opiomelanocortin) and 
CART (Codeine and amphetamine regulated transcript) which are anorexigenic 
neuropeptides that is stimulatory to satiety centre and inhibitory to feeding centre. 
Leptin stimulates POMC/CART while it inhibits NPY/AgRP group thus 
suppressing appetite100.   
  Leptin increases sympathetic outflow and activates brown adipose tissue 
thermogenesis. Leptin levels fall rapidly in response to fasting. It also slows down 
metabolic rate by decreasing thyroid hormone levels, mobilizes energy stores, and 
decreases insulin-like growth factor-1 (IGF-1) level (Ahima RS et al, 1996). 
 
Regulation of Insulin Sensitivity: 
Leptin improves insulin sensitivity by reducing plasma glucagon and 
growth hormone levels. Leptin similar to insulin increases fatty acid oxidation and 
skeletal muscle glucose. Leptin acts through insulin-signaling pathways, 
particularly phosphatidylinositol 3-kinase (PI3K) and 5-AMP-activated protein 
kinase (AMPK) activation. 
  Leptin acts as a signaling molecule released from the adipocytes acting on 
the endocrine pancreas controlling the insulin secretion in accordance with the 
[46] 
 
energy stores of the body, forming “Adipo-insular axis” which is a classic 
endocrine feedback loop.  
Leptin decelerates lipid deposition in adipose tissue promoting energy 
expenditure (Minokoshi Yet al 2002)101. Leptin has an insulin promoter activity 
and also effectively inhibits glucagon secretion from pancreatic cells. 
 
 
               Figure - 6   Role of Leptin 
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Regulation of Neuroendocrine Function: 
Leptin is found to be an important mediator of the hypothalamo-pituitary- 
gonadal axis. LH pulsatility and testosterone secretion was blunted in healthy lean 
men on fasting. Leptin replacement brought back these hormones to the prefasting 
levels. Similar effects were observed in normal weight women. Infertile ob/ob 
mice became fertile on exogenous leptin administration.   
Leptin regulates reproductive function by activating neurons that project 
afferent input to GnRH neurons in the preoptic area and other hypothalamus 
suggesting that leptin may mediate the reproductive axis through regulation of kiss 
peptins, products of the Kiss1 gene, as well as dynorphin and neurokinin B. (Roux 
N et al, 2003). Leptin threshold of 3ng/mL is necessary to signal the brain the 
message that energy stores in adipose tissue are adequate to bring pregnancy to 
term. 
 
Role of Leptin in Obesity: 
Elevated levels of leptin and hyperphagia are features of adult onset 
obesity. Leptin a potent inhibitor of food intake is expected to decrease insulin 
levels. This paradox is explained by the ‘selective leptin resistance’. 
Hyperleptinemia contributes to increased sympathetic activity and arterial pressure 
in obesity, with a resistance to the metabolic actions of leptin like satiety and 
weight reduction. This may be because of a suppressed central action due to the 
[48] 
 
saturation of receptors with a persistent peripheral action or due to leptin 
resistance. 
 Patients with congenital complete leptin deficiency due to homozygous 
leptin gene mutations develop extreme obesity from birth and have distinct 
neuroendocrine abnormalities, including hypogonadotropic hypogonadism with 
failure to reach puberty.  
 
 
   
                      Figure- 7   Role of Leptin in Obesity 
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Effect on Cardiovascular system: 
Plasma leptin concentration is a novel, independent risk factor for coronary 
events (Michael Wallace et al, 2001). Hyperleptinemia is associated with lower 
arterial distensibility, promotes angiogenesis and enhances the calcification of 
vascular cells and potentiates the pro-thrombotic platelet aggregation through a 
leptin receptor-dependent mechanism thus increasing the coronary risk. (Sierra-
Honigmann et al, 1998)102  
Leptin stimulates the sympathetic system, increases energy expenditure and 
leptin infusion is found to increase the catecholamines levels and thus produce an 
increased heart rate and blood pressure. A negative feedback loop is formed 
between leptin and the sympathetic nervous system by the catecholamines like 
norepinephrine, epinephrine and isoprenaline that have an inhibitory effect on 
leptin synthesis (Eikelis et al, 2003). 
Leptin exerts direct, non neural effects on cardiovascular function. Leptin 
receptors or their mRNA have also been detected in the heart and endothelium of 
blood vessels (Ren J et al). Leptin produces a nitric oxide dependent arterial 
vascular relaxation with the chloride ion being an important regulator in leptin-
induced endothelial NO release (Kimura et al. 2000) which serves as a counter-
balance for the enhanced sympathetic activity in response to leptin. 
The higher heart rate in the hyperleptinemia will impose a greater 
myocardial workload and therefore predispose the heart to pathological changes. 
[50] 
 
Leptin causes an increased oxygen consumption and decreased cardiac efficiency 
(Atkinson et al, 2002)103.  
 
Some of the actions of leptin on the cardiovascular system and the 
pathways involved are enlisted below. 
Leptin Action  Pathways Involved 
Liporegulation  Increased fatty acid oxidation 
Development of hypertension Increased catecholamine release, increase in 
preserved renal sympathetic nerve activity, Nitric 
oxide 
Development of atherosclerosis Endothelial cell Nitric oxide and reactive oxygen 
species (ROS) production 
proliferation and hypertrophy, platelet 
aggregation, proinflammatory cytokine 
production 
Impaired cardiomyocyte 
contractility 
JAK/STAT, NO-cGMP, G protein–coupled 
receptor, adenylate cyclase, Endothelin -1 (ET-
1), NAPDH, ROS 
Increase in size of cardiomyocyte Endothelin-1, Reactive Oxygen Species 
Enhanced cardiomyocyte mitosis 
and proliferation 
ERK1/2, p38, PI3K, peroxisome 
proliferator-activated receptor-α 
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Protection from 
ischemia/reperfusion injury 
PI3K, ERK1/2, Nitric oxide, Reactive Oxygen 
species 
Deficiency leads to increased rate 
of cardiomyocyte apoptosis 
p38, caspase-3, DNA damage, Angiotensin  II 
 
 
 
Chethan et al, in 2012104, conducted a comparative study of heart rate 
variability in normal and obese young adult males which include 50 controls and 
50 cases based on BMI. There was a significant reduction in SDNN, E/I ratio, HF 
nu and increase in LF nu and LF/HF in cases when compared to controls 
suggesting that there was a significant reduction in parasympathetic activity and 
increase in sympathetic activity. There was a shift in sympathovagal balance 
towards sympathetic predominance among obese males in contrast to normal 
males.  
 
Mehmet Erkan Altuncu et al in 2012105, conducted a study of short term 
analysis of  heart rate variability in 66 obese children and 40 healthy controls and 
found that high frequency parameter values were lower in obese compared to 
controls with p value of 0.046 and low frequency by high frequency ratio was 
found significantly higher p < 0.001. He also found insulin resistance in 50% of 
obese, dyslipidemia in 59%, hypertension in 27% and metabolic syndrome in 39% 
of patients in obese group.   
[52] 
 
Rajalakshmi et al in 2012106, conducted a study of heart rate variability on 
Indian obese young adults. The study included 60 young adults of whom 30 were 
obese and 30 normal weight groups. It was found Mean HR increased which they 
suggested to be due to relative sympathetic dominance and demonstrated a 
decrease in parasympathetic nerve activity. HRV indices significantly associated 
with obesity indices. It was also suggested that time and frequency domain 
analysis of HRV in obese shows imbalance in autonomic neural activity of heart.  
 
Masood Y Al Maskari et al and Adel A Alnaqdy et al in 2006107 , 
conducted a correlation study between serum Leptin levels, Body mass index and 
obesity in Omanis which included 35 obese and 20 non obese healthy subjects. 
There was a significant difference in serum leptin between the obese and the 
control group with significantly positive correlation between leptin levels in obese 
subjects with weight, body fat percentage and BMI.    
 
    
 
 
 
 
 
 

[53] 
 
3. AIM AND OBJECTIVES 
Aim:  
To evaluate Cardiovascular Autonomic Functions in Young Obese 
individuals and to estimate their serum leptin levels 
Objectives: 
 To assess and compare the cardiovascular autonomic functions in 
young obese individuals and the normal individuals  
 To estimate the serum leptin levels in young obese individuals and 
compare it with that of normal individuals 
 To correlate the serum leptin levels with HRV indices, body mass 
index and waist circumference in young obese individuals 
 To correlate the HRV indices with body mass index and waist 
circumference in young obese individuals 
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4. MATERIALS AND METHODS 
This study was conducted at Madras Medial College, Chennai, in the 
Institute of Physiology and Experimental Medicine, after obtaining the 
Institutional Ethical Committee clearance. The study was conducted on a group of 
50 young obese individuals with BMI ≥ 25  in the age group of 18 to 25yrs of both 
sexes and 50 age matched normal individuals with BMI 18.5 to 24.9 as controls 
from October, 2014 to August, 2015. The study included equal number of males 
and females. 25 males and 25 females in the control group and 25 males, 25 
females in the young obese group that is a total of 100 participants were included 
in the study.   
4.1. Selection of cases:  
Fifty young obese individuals of both sexes in the age group of 18-25yrs 
with body mass index ≥ 25 were selected from patients attending the outpatient 
department of endocrinology at ‘Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai – 3’  
Height and weight of the subjects were measured and BMI calculated using 
Quetelet’s index, named after Belgian astronomer Quetelet 
 BMI = Weight in Kg  
             Height in meter2 
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4.1.1. Inclusion criteria: 
Age group of 18 – 25 years  
Both sexes 
Body mass index ≥ 25  
4.1.2. Exclusion criteria:  
Pregnancy, Post- partum period  
Systemic disorders like diabetes and hypertension 
Respiratory, hepatic, neurological and cardiovascular disorder  
Any medical illness (i.e. respiratory and heart failure and renal disease)  
Hypothyroidism, Anaemia 
Neoplasia, any secondary infections  
Use of antidiabetic, antihypertensive, antiobesity drugs 
Use of glucocorticoids, oral contraceptives or any hormonal therapy within the 
previous 6 months 
Any infectious disease 
Fifty subjects fulfilling the above criteria were selected and they were 
assigned as the study group 
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4.2. Selection of controls:  
Fifty normal individuals with body mass index 18.5 - 24.99 of both sexes 
were chosen from the general population and they were assigned as the control 
group. 
 
4.3. Study design:   
Case - Control Study 
4.4. Materials required: 
Niviqure Ambulatory Digital ECG Recorder (INCO) 
Sphygmomanometer 
Hand grip Dynamometer 
Cold water basin that contain water at temperature of 4-6°C 
 
4.4.1. Description of the instruments: 
Niviqure Ambulatory Digital ECG Recorder: 
Niviqure ECG recorder is a digital, solid state, stand alone, multi load 
computerized recording system. It is designed to acquire ECG, analyze it and store 
[57] 
 
the ECG data over long hours. The data is acquired and it is stored in flash 
memory. The data can be later downloaded and further analysis done. The transfer 
of data from the flash memory module to the computer is via an interface RS233C 
which is a compatible module. 
 Niviqure has powerful processing software for online ECG study, for 
storage of data and off line data replay and study. The data can be transferred to 
other software for statistical analysis and Fast Fourier Transformation (FFT) 
analysis. The picture given below summarizes the individual steps followed while 
recording and processing the ECG data for analysis of HRV. 
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4.5. Methodology:  
After selection of subjects, an informed, written consent was obtained from 
the study group and also the control group.  
After taking a detailed history, their weight in kilograms and their height in 
meters were measured and their BMI was calculated as weight/height in meter 
square. Their WC and HC were measured and their WHR was calculated. 
WHR = Waist circumference 
               Hip circumference 
A thorough general as well as systemic examination was done. 5ml of 
blood samples were collected simultaneously for determining their leptin level.  
The procedures were explained to the subjects and the fifty study group and 
fifty controls were subjected to a battery of autonomic function tests including 
resting heart rate variability as Ewing et al has described. These tests examine the 
HRV and blood pressure at rest and their response to some of the manouvers 
which are normal physiologic stimuli. 
 Many factors both internal and external can confound the results of 
autonomic function tests. These confounding factors should be controlled. The 
precautions that are taken while performing the autonomic function tests are as 
follows: 
[59] 
 
 The subjects should be relaxed and comfortable without any significant 
anxiety, and free from recent acute illness.  
 The subjects were asked to empty the bladder before the test. 
 Compressive garments which are uncomfortable are to be avoided. 
 The autonomic function tests were carried out two hours after breakfast 
between 10 -12 AM.  
 Caffeine, nicotine and alcohol should be avoided 2 hours before testing. 
 The tests were performed in a quiet room , lighting subdued and with 
controlled, comfortable temperature ranging from 25-28° C 
 Electronic gadgets were removed, mobile phones were switched off.  
 The subjects were instructed about various maneuvers and allowed to 
practice these maneuvers. 
 The subjects were made to rest quietly for a minimum period of ten 
minutes, without moving, in the awake and supine position. 
Electrodes were placed in the following position after wiping the site with sprit.  
Electrode  Position 
Exploring electrode  Left shoulder 
Exploring electrode Right shoulder 
Exploring electrode Left subcostal 
Reference electrode Right subcostal 
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4.5.1. Resting Heart rate variability: 
The total period of rest was increased to 30 minutes. During this resting 
period, ECG was acquired for five minutes (320 seconds), by a continuous 
recording which is required for short term ECG analysis. The ECG data is 
screened for any artifact. After editing it, the results were fed to HRV analysis 
software.  
The analogue to the digital conversion of the resting ECG signal was done 
with sampling frequency of 1024/sec using AD converter. The converted ECG 
signal was analyzed under power spectrum using Fast Fourier Transformation 
(FFT) analysis.  
SDNN, Mean HR, normalized Low frequency (LF nu), normalized High 
frequency (HF nu), LF/HF ratio were all estimated. 
 
4.5.2. Orthostatic Standing Test: 
The subject was allowed a minimum of ten minutes rest in supine position. 
Then the subject was allowed to stand immediately within a few seconds without 
any support by putting equal weight on both the legs, for a period of five minutes. 
Pulse rate and blood pressure was recorded after 1 minute & 3 minutes.  
Photograph.1. Niviqure Ambulatory Digital ECG recorder 
 
 
 
 
 
 
 
 
 
 
 
 
Photograph.2. Recording of Resting HRV 
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Measurement of R-R interval was done at the15th beat which was 
minimum and at 30th beat which was maximum.  
30/15 ratio = RR interval at 30th beat 
            RR interval at 15th beat 
The variations in SBP and DBP after 1 minute of standing were recorded. 
The values are compared with normal values obtained from tcontrol group. 
 
4.5.3. Deep Breathing Test: 
The subject after being seated comfortably was asked to breathe deeply and 
slowly as per the verbal commands such that the subject inspires deeply for 5 
seconds and expires slowly for a period of 5 seconds. Thus one cycle of 
inspiration and expiration lasts for 10 seconds. Six such cycles were performed 
lasting for about 1 minute. 
 The average of RR intervals which are long and short during expiration 
and inspiration respectively for 6 cycles was obtained and from this the 
Expiration/Inspiration ratio was calculated. 
Expiration/Inspiration ratio = Longest RR interval during expiration 
                                                    Shortest RR interval during inspiration 
[62] 
 
 
The values were compared with normal values of control group. 
4.5.4. Valsalva Maneuver: 
The test was performed after another 5 minutes interval of rest in sitting 
posture. A forced expiration was done to maintain 40 mmHg pressure in the 
mercury manometer for a period of 15 seconds during which ECG was recorded 
and ECG recording was proceeded after maneuver for a duration of 30 seconds. 
Valsalva ratio calculated. 
VR= Longest RR interval after strain 
            Shortest RR interval during strain 
 
4.5.5. Isometric Handgrip Test: 
The patient was placed in supine and relaxed position and the blood 
pressure was recorded. A simple exercise using a hand grip dynamometer was 
performed by the subject, as instructed. The subject was asked to press the hand 
grip dynamometer with maximum force for few seconds and the same was 
repeated thrice. The highest reading was considered as Maximum Voluntary 
Contraction (MVC). Hand grid to attain 30% of MVC for duration of 5 minutes 
was done and blood pressure was measured in the opposite limb during the 
Photograph.3. Orthostatic standing test  
 
 
 
 
 
 
 
 
 
 
 
 
Photograph.4.Isometric Handgrip test 
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procedure and after the procedure.    Increase in DBP = DBP after procedure – 
Diastolic blood pressure at rest. 
 
4.5.6. Cold pressor test:  
Immersion of hand or feet inside the cold water (4°) for 60- 90 seconds 
cause activation of sympathetic system via afferent pain and temperature fibers of 
skin. There is a raise in diastolic blood pressure which predicts sympathetic 
activity.  
Results from all tests were statistically evaluated. Accordingly differences 
in autonomic functions in study and control group were assessed. 
 
4.6. Assessment of Serum leptin levels: 
4.6.1. Sample collection and storage: 
Under strict aseptic precautions about 5ml of blood was collected by 
venepuncture from the subjects and was centrifuged. Serum was separated, serum 
samples were stored at -20° Celsius. The samples were then transported under cold 
chain maintenance to Central Research Laboratory at Tamil Nadu Dr.MGR 
Medical University, Guindy, Chennai, for performing the test. DRG Diagnostics 
Photograph.5. Cold Pressor test 
 
 
 
 
 
 
 
 
 
 
 
 
Photograph.6. Sample collection  
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Leptin (Sandwich) Elisa kit was used for assessing serum leptin levels. 
Appropriate national biohazard safety guidelines were followed. 
 
 
4.6.2. Principle of the test: 
The DRG Leptin ELISA kit is a solid phase enzyme linked immunosorbent 
assay (ELISA) based on the sandwich principle.  
The microtiter wells are coated with a monoclonal antibody directed 
towards a unique antigenic site on a Leptin molecule.  Subjects sample containing 
endogenous Leptin is incubated in the coated microtitre wells which are then 
coated with a specific biotinylated monoclonal anti Leptin antibody. A sandwich 
complex is formed. After incubation the unbound material is washed off and a 
Sreptavidin Peroxidase Complex is added for detection of the bound Leptin. 
Having added the substrate solution, the intensity of colour developed is 
proportional to the concentration of Leptin in the given sample 
 
4.6.3. Reagents Required: 
1. Microtiter wells Plate with Break Apart Wells coated with monoclonal anti-
Leptin antibody  
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2. Standard (0-5) with concentrations 0-2-5-25-50-100 ng/ml 
3. Control (Low and High) 
4. Assay Buffer Leptin Calibrators 
5. Antiserum – Monoclonal biotinylated anti-Leptin antibody 
6. Enzyme Complex – Streptavidin conjugated to horseradish peroxidase  
7. Substrate Solution – Tetramethylbenzidine (TMB) 
8. Stop solution – 0.5M Sulphuric acid 
9. Wash Solution 
  
4.6.4. Other materials required  
A microtiter plate calibrated reader (450 ± 10 nm)  
Calibrated variable precision micropipettes 
Distilled water, absorbent paper, timer, semi logarithmic graph paper  
 
4.6.5. Assay procedure: 
All reagents and specimens were allowed to come to room temperature 
before use. Standard controls or samples about 15 μL each were added with new 
tips that are disposable into corresponding wells that were labeled. 
Photograph.7. DRG Leptin ELISA kit 
 
 
 
 
 
 
 
 
 
 
 
 
Photograph.8. ELISA Reader, TN Dr.M.G.R.Medical University  
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 Assay buffer about 100 μL was dispensed into each well. Then it was 
mixed for 10 seconds. It was then incubated for 2 hours at room temperature. Well 
contents were shaken out briskly. About 300 μL of wash solution was dispensed 
into each well to wash the wells. Wells were washed 3 times with diluted wash 
solution. Wells were stroke on absorbent paper to remove residual droplets. 
Antiserum about 100 μL each was dispensed. Then it was incubated at 
room temperature for 30 minutes. Well contents were shaken out. Wash procedure 
repeated and wells were stroke on absorbent paper. 
  100 μL of Enzyme Complex each was added and incubated at room 
temperature for 30 minutes. Then contents were shaken out. Wash procedure 
repeated and wells were stroke on absorbent paper.  
Substrate solution about 100 μL was dispensed and incubated at room 
temperature for 15 minutes. Stop Solution 50 μL each was dispensed to stop 
enzymatic reaction. Within 10 minutes using ELISA microtiter plate reader, 
absorbance was found at 450 ± 10 nm for all the wells. 
 
4.6.6. Calculation of Results: 
Absorbance (Optical density) values of standard controls and samples were 
calculated. With concentration on X axis and absorbance value on Y axis, plotting 
the mean absorbance got from each standard against its concentration, a standard 
[67] 
 
curve was constructed. Using this standard curve based on mean absordance value, 
corresponding concentration of each sample was found. 
Normal values in lean men are 2 to 5.6 ng/ml and in lean women are 3.6 to 
11.1ng/ml. 
Using the Statistical Package for Social Sciences (SPSS) software version 
21, all the data obtained from all the autonomic functions tests and serum leptin 
levels were analyzed.  
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5. RESULTS 
Data obtained from conducting the Autonomic Function Tests and Serum 
Leptin levels were statistically analyzed. Mean and standard deviation of the 
variables were determined for the control and young obese groups. Independent 
(Unpaired) t test was employed for statistical analysis as the test of significance at 
95% confidence interval. 
* P value < 0.05 was considered as significant 
** P value < 0.01 was considered as highly significant 
***P value < 0.001 was considered as very highly significant 
 
Comparison of physical characters among study groups: 
 
Table No: 1 compares the age and height of the controls and obese groups. The P 
value of age and height were not significant.  
TABLE NO:1 
COMPARISON OF AGE AND HEIGHT AMONG STUDY GROUPS 
VARIABLE STUDY GROUP N MEAN SD P-VALUE 
AGE(years) 
CONTROLS 50 20.10 1.05 
0.4163 
OBESE 50 20.38 2.18 
HEIGHT(m) 
CONTROLS 50 1.60 0.06 
0.179 
OBESE 50 1.58 0.07 
 
 
GRAPH NO: 1 COMPARISON OF AGE AMONG STUDY GROUPS 
 
 
   
GRAPH NO: 2  COMPARISON OF HEIGHT AMONG STUDY GROUPS 
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Comparison of obesity indices among study groups:  
TABLE NO: 2 
VARIABLE STUDY GROUP MEAN SD P-VALUE 
COMPARISON OF WEIGHT AMONG STUDY GROUPS 
WEIGHT(kg) 
CONTROLS 52.42 2.58 
0.000*** 
OBESE 78.86 5.62 
                                                                     ***  very highly significant 
COMPARISON OF BODY MASS INDEX AMONG STUDY GROUPS 
      BMI 
CONTROLS 20.48 1.09 
0.000*** 
OBESE 31.50 2.25 
                                                                  ***  very highly significant 
COMPARISON OF WAIST CIRCUMFERENCE (WC) AND HIP 
CIRCUMFERENCE (HC) AMONG STUDY GROUPS 
WC (cm) 
CONTROLS 75.26 1.91 
0.000*** 
OBESE 106.30 5.37 
HC (cm) 
CONTROLS 93.90 4.0 
0.000*** 
OBESE 107.34 5.81 
                                                                  ***  very highly significant 
COMPARISON OF WAIST HIP RATIO AMONG STUDY GROUPS 
WHR 
CONTROLS 0.80 0.04 
0.000*** 
OBESE 0.99 0.02 
                                                                    ***  very highly significant 
 
 
GRAPH NO: 3  COMPARISON OF WEIGHT AMONG STUDY GROUPS 
 
 
 
GRAPH NO: 4 COMPARISON OF BODY MASS INDEX AMONG STUDY GROUPS 
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GRAPH NO: 5 COMPARISON OF WAIST CIRCUMFERENCE AND HIP 
CIRCUMFERENCE AMONG STUDY GROUPS 
 
 
GRAPH NO: 6   COMPARISON OF WAIST HIP RATIO AMONG STUDY GROUPS 
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Table No: 2 compares the weight, body mass index, waist circumference, hip 
circumference and waist hip ratio of the controls and obese groups. The p value of 
all parameters were very highly significant. 
TABLE NO: 3 
COMPARISON OF RESTING SYSTOLIC AND DIASTOLIC 
BLOOD PRESSURE AMONG STUDY GROUPS 
VARIABLE STUDY GROUP MEAN SD P-VALUE 
RESTING 
SBP 
CONTROLS 112 6.34 
0.001** 
OBESE 116.72 7.57 
                                                                                               ** highly significant 
RESTING 
DBP 
CONTROLS 70.28 5.22 
0.012* 
OBESE 73.24 6.26 
                                                                                                             * significant 
Table No: 3  compares the resting SBP and the DBP among the study groups. The 
p value of the resting systolic blood pressure was highly significant and that of the 
resting diastolic blood pressure was also significant  
 
Comparison of Resting HRV among the study group: 
Comparison of time domain measures among the study groups: 
Table No: 4 compares the time domain measures namely SDNN and the 
Mean HR among the controls and the obese. The P value for SDNN was highly 
significant and that of the mean HR was very highly significant. 
[71] 
 
TABLE NO: 4 
COMPARISON OF SDNN AMONG STUDY GROUPS 
VARIABLE STUDY GROUP MEAN SD P-VALUE 
SDNN 
CONTROLS 60.14 15.50 
0.002** 
OBESE 52.20 8.39 
                                                                                             ** highly significant 
COMPARISON OF MEAN HEART RATE AMONG STUDY GROUPS 
MEAN HR 
CONTROLS 74.30 2.79 
0.000*** 
OBESE 77.06 4.18 
                                                                                 ***  very highly significant 
 
Comparison of Frequency domain measures among the study groups: 
TABLE NO: 5 
VARIABLE STUDY GROUP MEAN SD P-VALUE 
COMPARISON OF LF (nu) AMONG STUDY GROUPS 
LF nu 
CONTROLS 40.47 9.58 
0.000*** 
OBESE 56.21 10.95 
COMPARISON OF HF (nu) AMONG STUDY GROUPS 
HF nu 
CONTROLS 59.46 9.13 
0.000*** 
OBESE 43.86 11.12 
                                                                  ***  very highly significant 
COMPARISON OF LF (nu)/ HF (nu) RATIO AMONG STUDY GROUPS 
LF/HF 
RATIO 
CONTROLS 0.72 0.29 
0.000*** 
OBESE 1.42 0.59 
                                                                  ***  very highly significant 
 
 
 
GRAPH NO: 7  COMPARISON OF RESTING SYSTOLIC AND DIASTOLIC BLOOD 
PRESSURE AMONG STUDY GROUPS 
 
 
 
GRAPH NO : 8 COMPARISON OF SDNN AMONG STUDY GROUPS 
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GRAPH NO: 9 COMPARISON OF MEAN HEART RATE AMONG STUDY GROUPS 
 
  
 
GRAPH NO: 10 COMPARISON OF LF nu AND HF nu AMONG STUDY GROUPS 
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Table No: 5 compares the important Frequency Domain measures among the 
study groups. The P value of LF and HF were very highly significant. The P value 
of LF/HF ratio was also very highly significant. 
 
Comparison of Autonomic Function Tests among study groups: 
TABLE NO: 6 
COMPARISON OF ORTHOSTATIC STANDING TEST 
30/15 RATIO AMONG STUDY GROUPS 
VARIABLE STUDY GROUP MEAN SD P-VALUE 
30/15 
RATIO 
CONTROLS 1.16 0.04 
0.011* 
OBESE 1.11 0.11 
                                                                                               *  significant 
COMPARISON OF OS SYTOLIC BP AMONG STUDY GROUPS 
OST SBP 
CONTROLS 
-4.04 4.84 0.000*** 
OBESE 
2.96 6.65 
                                                                         ***  very highly significant 
COMPARISON OF OS DIASTOLIC BP AMONG STUDY GROUPS 
OST DBP 
CONTROLS 
-1.04 2.56 0.000*** 
OBESE 
1.44 3.36 
                                                                           ***  very highly significant 
 
 
GRAPH NO: 11 COMPARISON OF LF/HF RATIO AMONG STUDY GROUPS 
 
 
 
GRAPH NO: 12  COMPARISON OF ORTHOSTATIC STANDING TEST 30/15 
RATIO AMONG STUDY GROUPS 
 
 
0.72
1.42
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
CONTROLS OBESE
LF/HF RATIO
CONTROLS
OBESE
1.16
1.11
1.08
1.09
1.1
1.11
1.12
1.13
1.14
1.15
1.16
1.17
CONTROLS OBESE
OST 30/15 RATIO
CONTROLS
OBESE
[73] 
 
Table No: 6 compares the orthostatic standing test results among the study groups. 
Comparison of 30/15 ratio showed a statistically significant P value. The P value 
of orthostatic standing SBP and DBP at 1minute were very highly significant. 
TABLE NO: 7 
COMPARISON OF  DEEP BREATHING TEST 
EXPIRATION/INSPIRATION (E/I) RATIO AMONG STUDY GROUPS 
VARIABLE STUDY GROUP MEAN SD P-VALUE 
E/I RATIO 
CONTROLS 1.27 1.23 
0.017* 
OBESE 0.09 0.09 
                                                                                                  *  significant 
Table No: 7 compares the Expiration/Inspiration Ratio obtained by deep breathing 
test among study groups. The P value of E/I ratio was statistically significant.  
 
TABLE NO: 8 
COMPARISON OF VALSALVA RATIO (VR) AMONG 
STUDY GROUPS 
VARIABLE STUDY GROUP MEAN SD P-VALUE 
VR 
CONTROLS 1.37 0.16 
0.001** 
OBESE 1.28 0.12 
                                                                         **  highly significant 
 
 
 
GRAPH NO:13  COMPARISON OF ORTHOSTATIC STANDING SYSTOLIC AND 
DIASTOLIC BLOOD PRESSURE AMONG STUDY GROUPS 
 
 
GRAPH NO: 14  COMPARISON OF E/I RATIO AND VALSALVA RATIO AMONG 
STUDY GROUPS 
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Table No: 8 Compares the mean and standard deviation of Valsalva Ratio (VR) 
among the study groups. The P value obtained was highly significant.   
TABLE NO: 9 
COMPARISON OF ISOMETRIC HANDGRIP SYTOLIC AND DIASTOLIC 
BLOOD PRESSURE AMONG STUDY GROUPS 
VARIABLE STUDY GROUP MEAN SD P-VALUE 
IHG SBP 
CONTROLS 5.96 2.66 
0.019* 
OBESE 7.24 2.68 
*  significant 
IHG DBP 
CONTROLS 12.08 3.33 
0.004** 
OBESE 14.04 3.29 
**  highly significant 
COMPARISON OF COLD PRESSOR TEST DIASTOLIC BLOOD PRESSURE 
AMONG STUDY GROUPS 
CPT DBP 
CONTROLS 8.20 2.11 
0.005** 
OBESE 9.76 3.17 
**  highly significant 
 
Table No: 9 Compares the raise in SBP and DBP in Isometric handgrip test and 
raise in diastolic blood pressure in the Cold pressor test among the controls and the 
obese groups. The P value of the isometric handgrip systolic BP was statistically 
[75] 
 
significant while the isometric handgrip diastolic BP was highly significant and 
the Cold pressor test diastolic BP was also highly significant. 
  
TABLE NO: 10 
COMPARISON OF SERUM LEPTIN LEVELS AMONG STUDY GROUPS 
VARIABLE STUDY GROUP MEAN SD P-VALUE 
S.LEPTIN 
CONTROLS 6.92 4.62 
0.000 
OBESE 24.28 7.63 
                                                                         ***  very highly significant 
 
Table No: 10 compares the serum leptin levels among the study groups. The P 
value was very highly significant. 
  
TABLE NO: 11 
CORRELATION OF SERUM LEPTIN LEVELS  
WITH OBESITY AND HRV INDICES 
S.LEPTIN BMI WC LF nu HF nu LF/HF 
‘r’ 0.62 0.42 0.52 -0.50 0.51 
                                                                   ‘r’ is Pearson’s correlation co efficient 
Table No: 11 shows the correlation of serum leptin levels in obese individuals 
positively correlated with BMI and WC. It also shows the correlation of serum 
 
 
GRAPH NO: 15  COMPARISON OF ISOMETRIC HAND GRIP SYSTOLIC, DIASTOLIC BP 
AND COLD PRESSOR TEST DIASTOLIC BP AMONG STUDY GROUPS 
 
 
GRAPH NO: 16  COMPARISON OF SERUM LEPTIN LEVELS AMONG STUDY 
GROUPS 
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leptin with HRV indices LF, HF, LF/HF ratio. Leptin is positively correlated with 
LF and LF/HF ratio while it shows negative correlation with HF. 
  
TABLE NO: 12 
CORRELATION OF HRV INDEX (LF/HF) WITH BMI AND WC  
HRV- LF/HF RATIO BMI WC 
‘r’ 0.59 0.57 
                                                                    ‘r’ is Pearson’s correlation co efficient 
 
Table No: 12 shows the correlation of HRV index LF/HF ratio in obese group with 
BMI and WC both being positively correlation. 
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6. DISCUSSION 
The purpose of the present study was to evaluate the cardiovascular 
autonomic functions and assess the serum leptin levels in young obese individuals. 
The study was aimed at including fifty young obese individuals of the age 19 to 25 
years with BMI ≥ 25 of both sexes and fifty age matched normal controls with 
BMI of 18.5 -24.9.  
There was a marked difference in the weight of the controls and the cases. 
The P value was 0.000 which was very highly significant. The BMI of the controls 
was 20.48± 1.09 and that of the obese was 31.50± 2.25. The P value was less than 
0.0001, very highly significant.   
The waist circumference of the obese group was increased significantly 
when compared to the controls. There was also a significant increase in the Hip 
Circumference of the obese. The WHR of the controls was 0.80 ± 0.04 and that of 
the young obese was 0.99 ± 0.02. The p value was 0.000 which was very highly 
significant.  
Rajalakshmi et al has shown similar differences in physical characters 
among the controls and obese in her study. Waist circumference and waist to hip 
ratio are direct indicators of abdominal obesity that is visceral fat. A greater waist 
to hip ratio and increased waist circumference were independently associated with 
a significantly increased risk of coronary heart disease (Yusuf S et al, 2004)108 
[78] 
 
Resting Blood Pressure: 
 The resting systolic blood pressure in the controls was 112 ± 6.34 while the 
resting systolic blood pressure in the obese group was 116.72± 7.57, which was 
significantly higher with a p value of 0.001. The resting diastolic blood pressure of 
controls was 70.28 ± 5.22 where as it was significantly higher that is 73.28 ± 6.26 
in the obese group with a statistically significant p value of 0.012. 
Both the systolic and the diastolic blood pressure were within normal range 
but with a significant difference among the study groups. Those who were known 
hypertensive were not included in this study as hypertensive subject show altered 
ANS functions as stated by Julius et al. 
This increase in blood pressure in obesity could be attributed to direct effect 
of obesity on hemodynamics such as increase in blood volume, stroke volume and 
cardiac output and mechanisms linking obesity to increase in peripheral vascular 
resistance such as endothelial dysfunction and effect of cytokines (Bjorntop et al, 
1990)109. The risk of hypertension is increased in obesity (Stamler R et al)110.  
The study was accomplished using resting HRV and a battery of 
cardiovascular autonomic function tests and assessment of serum leptin was done. 
The integrity of sympathetic and parasympathetic components of the autonomic 
nervous system and the sympathovagal balance were assessed and thereby 
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substantiate the role of autonomic dysfunction and leptin in obesity and its 
comorbidities. 
The cardiovascular autonomic functions are strongly influenced by 
sympathetic and parasympathetic divisions. The sympathetic nervous system has 
the control on the myocardial contractility and heart rate where as the 
parasympathetic effect is essentially on the heart rate. 
 
Time Domain Measures of Resting HRV: 
 The SDNN in the control group was 60.14 ± 15.50 and that in the obese 
was 52.20 ± 8.39. The difference in the value shows that there is a significant 
decrease of standard deviation of normal to normal interval (SDNN) in the obese 
group with a p value of 0.002.Chethan et al has shown similar results in his study. 
 Similar results were shown by Emdin M et al, 2001111. Similar findings of 
reduced SDNN in obese have been shown by Archana et al, 2013112.  A reduction 
in SDNN, a parameter which reflects parasympathetic activity in this study implies 
a reduction in parasympathetic activity in obese.   
The Mean HR in the control group was 74.30 ± 2.79 while the mean heart 
rate in the obese group was raised to 77.06 ± 4.18 with a very highly significant p 
value of 0.000. Though the mean HR in both the groups are within normal limits 
[80] 
 
there is a significant increase in mean HR in the obese group which could be 
attributed to parasympathetic withdrawal in the obese 
 Rajalakshmi et al has got similar results in her study. This could be due to 
hemodynamic changes in obesity. An increase in body weight is associated with 
an increase in mean heart rate due to decline in parasympathetic tone as stated by 
Hirsch J et al in his study113.  Palatini et al has stated in his study that higher heart 
rate could be a marker of relative sympathetic dominance and is an independent 
marker of mortality in various conditions.  
Though the time domain parameters yields better results in 24 hour Holter 
monitoring than short term resting HRV monitoring which was used in this study 
as stated by Saul JP et al, a significant decrease in SDNN and increase in mean 
HR indicates parasympathetic withdrawal. 
 
Frequency Domain Measures of Resting HRV:  
This study shows a highly significant variation in frequency domain 
variables. The LF and HF values are altered by the total power changes. To 
minimize this effect normalized values are taken. The Low Frequency in 
normalized units in the controls was 40.47 ± 9.58 and in the obese was 
56.21±10.95, with very highly significant increase in the obese with a P value of 
0.000 which indicates an increase in the sympathetic activity in the obese group.    
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The HF nu in the controls was 59.46 ± 9.13 and in the obese was 43.86 ± 
11.12 which shows a very highly significant decrease in the obese group with a P 
value of 0.000 which implies parasympathetic withdrawal as HF nu is an indicator 
of vagal activity. 
The LF/HF ratio which is an accurate measure of sympathovagal balance 
has increased in the obese group when compared to the control group with a very 
highly significant P value of 0.000, which implies overall sympathovagal 
imbalance in the obese with sympathetic over activity and parasympathetic 
withdrawal. These results were consistent with the results of the studies of 
Rajalakshmi et al, Chethan et al and Archana et al. Mehmet Erkan Altuncu et al, 
Karason k et al and Chen- chu fu et al in their studies have shown similar results.    
 
Orthostatic Standing Test: 
The cardiovascular reflex changes on active standing after a period of rest 
in supine posture provides information on the integrity the baroreflex pathway. 
There occurs pooling of blood in the lower extremities on standing due to gravity 
which causes a reduced cardiac output and an immediate fall in BP. This is 
accompanied by an increase in heart rate which is recorded as a maximum 
decrease in RR interval, a maximum at about the 15th beat. Contraction of the 
limb and abdominal vessels on active standing causes an increased venous return 
and a rise in BP which results in the slowing of heart rate which is recorded as an 
increase in RR interval a maximum at about the 30th beat (Borst et al).  
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Thus the ratio of the maximum RR interval and the minimum interval 
which is the 30/15 ratio is a measure of parasympathetic activity. The blood 
pressure response to active standing is a function of sympathetic system.  
In this study, the orthostatic standing test 30/15 ratio was decreased in the 
obese group (1.11±0.11) when compared to the control group (1.16±0.04) with 
significant P value of 0.011, which indicates a decreased parasympathetic activity 
in the obese.  
After 1-3 minutes of standing, the systolic blood pressure of the controls 
showed a fall of 4.04± 4.84 mm Hg while that of the obese group showed an 
increase of 2.96 ± 6.65 mm Hg with a significant P value of 0.000 and the 
diastolic blood pressure of the control group showed a fall of 1.04±2.56 mm Hg 
while that of the obese group showed an increase in diastolic blood pressure by 
1.44±3.36 with a significant P value of 0.000. These findings substantiate 
sympathetic over activity in the obese group. 
 
Deep breathing test:  
The principle behind this test is sinus arrhythmia. During inspiration the 
heart rate increases and the reverse occurs in expiration. The ratio between the 
longest RR interval during expiration and the shortest interval during inspiration 
(E/I ratio) are calculated and compared between the study groups. 
The E/I ratio in the obese group (0.09 ± 0.09) was significantly reduced 
when compared with the control group (1.27 ± 1.23) with a P value of 0.017. This 
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result was consistent with results shown by Chethan et al in his study. The 
decrease in E/I ratio in obese individuals suggests a decreased vagal action that 
parasympathetic withdrawal. 
 
Valsalva maneuver: 
The Valsalva ratio is calculated by the ratio of the longest RR interval after 
the strain (phase IV) and the shortest RR interval during the strain (phase II). It is 
a measure of parasympathetic function. To measure blood pressure accurately in 
the four phases of the maneuver is difficult manually by sphygmomanometer, 
which requires a beat to beat blood pressure monitor. 
 VR in the obese (1.28 ± 0.12) was significantly lower as compared to the 
controls (1.37 ± 0.16) with p value of 0.001 which implies decrease in 
parasympathetic activity. Valsalva ratio ≥ 1.21 is considered as normal in younger 
age group (Ewing et al). 
 
Isometric handgrip test: 
Sustained isometric hand grip against resistance causes an increase in heart 
rate and arterial blood pressure. This cardiovascular reflex is sympathetically 
mediated and one of the simple non invasive measures of sympathetic reactivity of 
autonomic nervous system that reflects the activity of peripheral sympathetic 
system (Bannister et al). Thus, the normal response is increase in the diastolic 
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blood pressure and heart rate after the maximum voluntary contraction was 
continued for one minute. 
In this study, the systolic blood pressure in the obese was higher than that 
of the controls with a significant P value of 0.019. The diastolic blood pressure of 
the obese was 14.04 ± 3.29 which was higher than that of the controls (12.08 
±3.33) with a significant p value 0.004. This result substantiates that there is an 
increased sympathetic activity in the obese group.   
 
Cold pressor test: 
  The cold pressor test helps in assessing the sympathetic nervous system. 
The normal response to immersion of a hand in ice water involves reflex arterial 
vasoconstriction producing increase in blood pressure and cardiac output by 
activation of afferent temperature, pain receptors in the skin. The sympathetic 
activation causes increase in diastolic blood pressure.  
The diastolic blood pressure of the control group was 8.20 ± 2.11and that of 
the obese group was 9.76 ± 3.17 with a significant P value 0.004. The increase in 
the diastolic blood pressure in the obese substantiates sympathetic over activity.  
 
Serum Leptin levels: 
On assessing by ELISA method, we could find that the serum leptin level in 
the control group (6.92 ± 4.62) and that of the obese group (24.28 ± 7.63) showed 
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a great difference. The obese group showed a very significant high level of serum 
leptin with a P value of 0.00. Many of the early studies have shown similar results.  
Masoud Y Al Maskariet al and Adel A Alnaqdy et al have shown similar 
findings in their study. This present study result is consistent with hyperleptinemia 
in obesity. Leptin receptor tolerance could be a cause for such an elevated level of 
leptin in obesity. Its level also positively correlated with BMI and sympathetic 
HRV parameter LF and may be associated with the cardiovascular risks in obesity.   
 
Correlation of serum leptin levels with HRV and obesity indices: 
The serum leptin levels of the young obese individuals had a positive 
correlation with the obesity indices namely body mass index and waist 
circumference. Thus an increase in BMI and waist circumference may be 
associated with elevated leptin levels and hence an increased cardiovascular risk. 
 The leptin levels in obese also had a positive correlation with LF nu which 
is an indicator of sympathetic parameter of HRV, negative correlation with the HF 
nu, an indicator of parasympathetic activity, and a positive correlation with LF/HF 
ratio the marker of sympathovagal balance. This result suggests that a raise in 
leptin level is prone to cause a raise in sympathetic hyperactivity leading on to 
autonomic dysfunction. 
 
[86] 
 
Correlation of HRV index (LF/HF) with BMI and Waist Circumference: 
LF/HF ratio, the major indicator of sympathovagal balance shows a 
positive correlation with the body mass index and waist circumference in young 
obese group and hence an increase in body mass index and waist circumference as 
in obesity is associated with autonomic dysfunction.  
Thus the evaluation of all these findings from all the autonomic function 
tests done suggest autonomic dysfunction in young obese individuals with 
parasympathetic withdrawal and sympathetic predominance, and associated with 
an elevated level of serum leptin which may have a role in the etiopathogenesis of 
obesity and its comorbidities with increased cardiovascular risks. 
 
Limitations of the study: 
A prospective study with a follow up after weight reduction would be 
preferred. It would have been better if Catecholamine hormonal assay that is a 
direct measure of sympathetic system were also done. 
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7. CONCLUSION 
Autonomic Function tests in young obese individuals indicate that there is a 
definite sympathovagal imbalance in the form of sympathetic overactivity and 
parasympathetic withdrawal. Chronic activation of the sympathetic nervous 
system makes them more prone for adverse cardiovascular events at an early age.  
In young obese individuals, Serum leptin levels are significantly higher 
correlating with BMI and waist circumference thus playing a role in 
etiopathogenesis of obesity and in increasing the cardiovascular risks and other co 
morbidities. Serum leptin levels correlated well with HRV parameters 
substantiating its role in stimulating the sympathetic nervous system. 
The battery of autonomic function tests is an effective tool in identifying 
the autonomic dysfunction at an earlier stage. Understanding the role of the 
sympathetic nervous system and the serum leptin levels in obesity might help in 
the treatment of obesity and prevent further complications in this disease. Further 
studies with hormonal assays would warrant a better understanding of the 
etiopathogenesis of obesity and other associated metabolic complications  
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8. SUMMARY  
Obesity is a common nutritional health problem associated with metabolic 
and hemodynamic changes that lead to increased cardiovascular risks affecting a 
wide spectrum of age groups. We aimed at evaluating the cardiovascular 
autonomic functions and serum leptin levels in normal young obese individuals. 
50 young obese with BMI ≥ 25, of both sexes aged 18 to 25 years and 50 
age matched normal individuals of both sexes with BMI 18.5 to 24.9 were 
subjected to a battery of autonomic function tests including resting HRV and their 
serum leptin levels were assessed using ELISA method.  
On analyzing the data obtained from the study, we could find that young 
obese individuals had autonomic dysfunction with sympathetic predominance and 
parasympathetic withdrawal, and their serum leptin level was elevated and 
correlated well with BMI. Sympathovagal imbalance with parasympathetic 
inhibition and sympathetic overactivity and elevated levels of leptin plays a vital 
task in etiopathogenesis of obesity and its comorbidities especially the increased 
cardiovascular risks.  
Early diagnosis of autonomic dysfunction using the non invasive autonomic 
function tests could help in the prevention of adverse cardiac events by early 
intervention by life style modification with alterations in the dietary pattern and 
physical activities so as to reduce weight. 
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(or it has been read to me). I was free to ask any questions and they have 
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choice, hereby give my consent to be included as a participant in 
 
“A study of Cardiovascular Autonomic Functions and Serum 
Leptin Levels in Young Obese individuals” 
 
1. I have read and understood this consent form and the information 
provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the 
investigator. 
5. I have been informed the investigator of all the treatments I am taking or 
have taken in the past ________ months including any native (alternative) 
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6. I have been advised about the risks associated with my participation in 
this study. 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms.  
8. I have not participated in any research study within the past 
_________month(s).  
9. I am aware of the fact that I can opt out of the study at any time without 
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hospital.  
10. I am also aware that the investigator may terminate my participation in 
the study at any time, for any reason, without my consent.  
12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented. 
13. I have understand that my identity will be kept confidential if my data 
are publicly presented. 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given 
in this document has been clearly explained to me and understood by me, I 
will be given a copy of this consent document. 
 
For adult participants: 
 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent) 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
 
Name and Signature of impartial witness (required for illiterate 
patients): 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining 
consent: 
 
Name _________________________ Signature_________________  
 
Date________________ 
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நாள்: 
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PROFORMA 
 
Name: 
Age: 
Sex: 
Address: 
Occupation: 
 
Complaints/duration: 
History of present illness: 
Past history: 
Personal history: 
 
History of any drug intake: 
History of associated illness: 
a. Diabetes 
b. Hypertension 
c. Ischemic heart disease 
d. Respiratory diseases 
e. Renal diseases 
Investigations : 
Fasting & post prandial blood Sugar 
 Serum electrolytes 
Lipid profile 
Thyroid profile 
S.Testosterone 
 
General examination: 
Temperature:                                                       
Pulse rate: 
Blood pressure: 
Height: 
Weight: 
BMI:  wt in kg / Ht2 in m2 
Waist hip ratio: 
 
Systemic examination: 
Cardiovascular system: 
Respiratory system: 
Gastrointestinal system: 
Central nervous system: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART CONTROLS 
S.NO 
AGE 
(YRS) 
SEX 
(M/F) 
Ht 
(m) 
Wt 
(Kg) 
BMI 
(kg/m2) 
WAIST 
(cms) 
HIP 
(cms) 
WHR 
SBP 
(mm Hg) 
DBP 
(mm Hg) 
Mean HR 
(/min) 
SDNN 
(msec) 
LF nu HF nu LF/HF 
OST 
30/15 
ratio 
OST 
SBP1 
OST 
DBP1 
E/I ratio VR IHG SBP IHG DBP CPT DBP 
S.Leptin 
(ng/ml) 
1 19 F 1.62 50 19.05 74 92 0.80 114 70 72 43 46.8 54.2 0.86 1.15 -8 -2 1.42 1.34 6 12 6 4 
2 21 M 1.71 58 19.84 76 88 0.86 110 68 70 68 43.3 56.7 0.76 1.12 -4 -4 1.22 1.21 4 10 8 2 
3 18 F 1.68 54 19.13 72 94 0.77 118 72 74 83 55.6 44.4 1.25 1.08 -2 0 1.32 1.38 8 14 10 1 
4 19 M 1.7 55 19.03 73 86 0.85 98 60 70 65 33.7 66.3 0.51 1.16 -6 -2 1.28 1.24 6 10 6 3 
5 22 M 1.55 52 21.64 75 87 0.86 110 60 72 53 45.8 54.2 0.85 1.09 -2 0 1.18 1.54 2 8 8 2 
6 21 M 1.58 52 20.83 77 89 0.87 110 70 71 37 48.5 51.7 0.94 1.19 4 0 1.24 1.29 4 14 10 8 
7 20 F 1.68 54 19.13 76 92 0.83 112 70 74 76 32.7 66.3 0.49 1.18 -8 -6 1.2 1.43 10 16 6 9 
8 19 F 1.67 54 19.36 75 94 0.80 106 66 73 64 52.7 47.3 1.11 1.13 -4 -2 1.22 1.25 8 10 8 12 
9 20 M 1.57 53 21.50 76 90 0.84 110 70 72 52 47.8 55.2 0.87 1.21 -6 -4 1.18 1.63 4 8 8 7 
10 21 M 1.62 55 20.96 74 87 0.85 120 78 70 66 37.9 63.1 0.60 1.23 -2 0 1.3 1.32 6 12 10 11 
11 21 F 1.63 54 20.32 75 89 0.84 108 76 74 94 43.4 56.6 0.77 1.12 4 2 1.26 1.29 4 10 8 8 
12 20 M 1.61 56 21.60 76 88 0.86 110 72 76 51 45.4 54.6 0.83 1.08 -10 -4 1.24 1.22 4 10 12 1 
13 19 F 1.55 52 21.64 78 96 0.81 100 60 74 49 56.4 43.6 1.29 1.15 8 4 1.22 1.27 2 8 10 10 
14 19 F 1.65 52 19.10 75 94 0.80 108 70 72 89 39.3 60.7 0.65 1.19 -2 0 1.21 1.62 10 18 8 13 
15 18 F 1.56 50 20.55 74 92 0.80 110 70 74 91 34.9 65.1 0.54 1.16 -6 0 1.44 1.18 4 10 6 9 
16 21 M 1.54 51 21.50 74 86 0.86 112 72 78 48 49.5 50.5 0.98 1.18 -8 -4 1.24 1.21 2 8 8 6 
17 21 F 1.6 51 19.92 75 90 0.83 106 68 74 50 48.6 58.4 0.83 1.13 -4 -2 1.34 1.33 4 10 8 11 
18 22 M 1.55 50 20.81 76 94 0.81 110 72 72 56 22.8 77.2 0.30 1.21 -6 0 1.38 1.26 8 14 8 4 
19 20 M 1.62 52 19.81 74 96 0.77 110 74 76 64 53.2 46.8 1.14 1.09 6 2 1.22 1.36 12 16 10 6 
20 21 M 1.69 54 18.91 75 95 0.79 120 70 75 51 26.7 73.3 0.36 1.14 -6 0 1.24 1.24 6 14 6 7 
21 19 F 1.62 50 19.05 76 97 0.78 108 62 74 48 40.9 59.1 0.69 1.11 8 4 1.23 1.65 2 12 8 14 
22 18 M 1.68 54 19.13 74 89 0.83 118 74 73 37 43.8 56.7 0.77 1.08 -6 0 1.28 1.32 4 8 6 6 
23 21 F 1.6 54 21.09 74 88 0.84 120 74 72 38 31.6 68.4 0.46 1.12 -10 4 1.36 1.21 8 16 4 10 
24 21 F 1.57 52 21.10 73 87 0.84 122 72 78 53 50.8 49.2 1.03 1.1 -8 -4 1.26 1.66 12 18 8 9 
25 20 F 1.54 52 21.93 75 92 0.82 118 74 74 36 59.3 40.7 1.46 1.14 -8 -2 1.17 1.28 6 14 12 17 
MASTER CHART CONTROLS 
S.NO 
AGE 
(YRS) 
SEX 
(M/F) 
Ht 
(m) 
Wt 
(Kg) 
BMI 
(kg/m2) 
WAIST 
(cms) 
HIP 
(cms) 
WHR 
SBP 
(mm Hg) 
DBP 
(mm Hg) 
Mean HR 
(/min) 
SDNN 
(msec) 
LF nu HF nu LF/HF 
OST 
30/15 
ratio 
OST 
SBP1 
OST 
DBP1 
E/I ratio VR IHG SBP IHG DBP CPT DBP 
S.Leptin 
(ng/ml) 
26 20 M 1.55 51 21.23 76 97 0.78 110 70 75 68 26.3 73.7 0.36 1.08 -4 -4 1.28 1.52 10 18 10 2 
27 21 F 1.59 50 19.78 77 97 0.79 108 68 80 39 44.5 54.5 0.82 1.18 -6 0 1.26 1.22 4 8 8 3 
28 20 M 1.6 52 20.31 76 96 0.79 110 64 78 57 29.8 67.2 0.44 1.16 -2 2 1.32 1.24 6 12 8 6 
29 19 F 1.58 50 20.03 74 95 0.78 118 72 72 49 42.4 57.6 0.74 1.22 -6 -4 1.46 1.36 4 8 10 14 
30 21 M 1.57 49 19.88 75 98 0.77 120 74 74 64 36 64 0.56 1.19 8 4 1.26 1.31 6 14 8 9 
31 19 M 1.45 47 22.35 80 97 0.82 104 66 73 74 23.7 64.3 0.37 1.16 -4 0 1.38 1.42 8 16 6 2 
32 22 M 1.53 48 20.50 77 95 0.81 114 72 75 57 40.2 59.8 0.67 1.18 -6 -2 1.16 1.38 8 14 10 7 
33 21 F 1.48 48 21.91 79 96 0.82 110 70 80 76 25.7 74.3 0.35 1.22 8 4 1.24 1.26 10 16 8 19 
34 20 M 1.78 59 18.62 78 97 0.80 112 68 79 69 30.4 69.6 0.44 1.16 -6 0 1.42 1.21 6 10 4 2 
35 21 F 1.58 48 19.23 75 98 0.77 98 60 74 73 26.1 73.9 0.35 1.18 -8 -2 1.24 1.54 8 14 6 3 
36 20 M 1.59 49 19.38 76 98 0.78 110 70 72 77 42.7 57.3 0.75 1.16 -4 0 1.16 1.62 6 18 8 1 
37 20 F 1.68 55 19.49 78 99 0.79 120 80 73 83 32.7 67.3 0.49 1.14 -8 -4 1.42 1.24 4 8 6 12 
38 19 M 1.58 51 20.43 78 97 0.80 116 74 78 52 43.4 56.6 0.77 1.19 -8 -2 1.23 1.32 4 10 6 4 
39 20 M 1.57 52 21.10 77 96 0.80 114 70 75 61 38.5 61.5 0.63 1.15 -4 0 1.22 1.19 2 8 8 3 
40 21 F 1.55 53 22.06 74 95 0.78 120 76 78 55 56.6 43.4 1.30 1.21 -4 -4 1.14 1.23 6 18 14 9 
41 20 F 1.53 51 21.79 73 94 0.78 116 62 79 51 45.4 54.6 0.83 1.08 -6 0 1.26 1.72 8 14 8 1 
42 20 F 1.65 53 19.47 74 96 0.77 100 64 72 90 34.9 65.1 0.54 1.14 -6 -2 1.16 1.27 10 16 12 10 
43 19 M 1.7 55 19.03 70 96 0.73 108 68 70 50 38.4 61.6 0.62 1.19 -4 0 1.24 1.34 4 10 10 2 
44 21 M 1.54 53 22.35 72 97 0.74 124 82 73 46 41.8 58.2 0.72 1.22 -8 -4 1.32 1.61 6 8 6 3 
45 18 F 1.55 52 21.64 76 98 0.78 110 74 73 61 38.5 61.5 0.63 1.16 -6 -4 1.48 1.48 4 10 8 8 
46 20 F 1.63 56 21.08 78 99 0.79 104 68 74 42 31.6 68.4 0.46 1.19 -4 -2 1.25 1.52 8 14 12 4 
47 21 M 1.6 55 21.48 76 96 0.79 118 70 80 82 55.6 44.4 1.25 1.18 -10 0 1.23 1.26 2 10 8 1 
48 20 F 1.59 54 21.36 73 98 0.74 120 80 78 46 29.6 71.4 0.41 1.15 -6 -4 1.42 1.32 8 10 6 11 
49 20 F 1.58 53 21.23 75 99 0.76 118 78 72 67 30.6 69.4 0.44 1.16 -8 -4 1.25 1.68 4 8 8 15 
50 21 M 1.62 56 21.34 74 99 0.75 110 70 74 56 46.8 53.2 0.88 1.18 -4 0 1.24 1.54 6 12 10 5 
MASTER CHART CASES 
S.NO 
AGE 
(YRS) 
SEX 
(M/F) 
Ht 
(m) 
Wt 
(Kg) 
BMI 
(kg/m2) 
WAIST 
(cms) 
HIP 
cms) 
WHR 
SBP 
(mm Hg) 
DBP 
(mm Hg) 
Mean 
HR 
(/min) 
SDNN 
(msec) 
LF 
nu 
HF nu LF/HF 
OST 
30/15 
ratio 
OST 
SBP
1 
OST 
DBP
1 
E/I 
ratio 
VR 
IHG 
SBP 
IHG 
DBP 
CPT 
DBP 
S.Leptin 
(ng/ml) 
1 22 F 1.58 82 32.85 112 116 0.97 120 70 74 46 48.6 51.4 0.95 1.13 6 16 1.18 1.16 8 4 6 30 
2 19 M 1.7 90 31.14 106 106 1.00 104 64 72 42 57.2 42.8 1.34 1.16 8 10 1.21 1.21 4 0 12 16 
3 23 M 1.62 89 33.91 114 111 1.03 100 62 75 55 64.3 35.7 1.80 1.08 4 14 1.19 1.23 6 2 8 15 
4 20 F 1.54 78 32.89 109 116 0.94 98 60 78 45 52.4 47.6 1.10 1.14 12 14 1.14 1.17 -8 -2 14 31 
5 19 F 1.57 81 32.86 110 114 0.96 114 68 76 38 54.7 45.3 1.21 1.08 10 18 1.18 1.16 4 0 10 24 
6 20 M 1.63 82 30.86 107 106 1.01 124 72 74 44 56.2 43.8 1.28 1.22 4 14 1.24 1.56 -4 -2 8 17 
7 18 F 1.53 76 32.47 113 115 0.98 110 66 74 57 64.3 35.7 1.80 1.12 8 12 1.13 1.14 6 2 12 23 
8 18 M 1.61 80 30.86 108 107 1.01 100 64 77 42 57.2 42.8 1.34 1.19 6 14 1.22 1.22 -6 -4 10 20 
9 21 M 1.64 80 29.74 104 103 1.01 116 60 75 58 61.2 38.8 1.58 1.14 8 14 1.25 1.38 -4 0 10 19 
10 22 M 1.66 79 28.67 100 100 1.00 100 64 74 56 43.6 56.4 0.77 1.21 4 10 1.32 1.42 -2 0 8 18 
11 24 F 1.59 78 30.85 107 109 0.98 118 70 73 52 64.2 35.8 1.79 1.18 10 16 1.14 1.12 4 0 16 22 
12 22 F 1.65 83 30.49 106 108 0.98 130 72 78 49 52.8 47.2 1.12 1.13 8 12 1.09 1.26 8 2 10 25 
13 18 M 1.58 70 28.04 100 101 0.99 124 72 73 52 66.4 33.6 1.98 1.21 12 14 1.33 1.54 -8 -4 4 16 
14 20 M 1.72 84 28.39 101 101 1.00 120 74 72 54 32.6 67.3 0.48 1.18 8 12 1.32 1.41 -2 0 10 11 
15 19 F 1.52 74 32.03 104 106 0.98 124 72 84 39 52.4 47.6 1.10 1.03 10 18 1.35 1.34 4 4 6 27 
16 21 F 1.4 68 34.69 112 115 0.97 128 66 79 52 54.5 45.5 1.20 0.86 8 12 1.12 1.16 12 6 18 32 
17 18 F 1.51 73 32.02 108 112 0.96 120 68 75 65 66.7 33.3 2.00 1.13 6 14 1.18 1.31 4 2 14 24 
18 19 F 1.59 69 27.29 99 102 0.97 114 74 76 58 59.1 40.9 1.44 1.22 4 10 1.24 1.46 6 0 8 25 
19 22 M 1.6 70 27.34 102 103 0.99 110 72 74 54 46.8 54.2 0.86 1.21 6 8 1.33 1.38 -4 -2 6 16 
20 23 F 1.54 73 30.78 107 109 0.98 116 70 72 66 53.4 46.6 1.15 1.14 4 12 1.16 1.26 6 0 10 19 
21 18 M 1.62 84 32.01 105 104 1.01 124 74 83 43 59.8 40.2 1.49 0.94 8 10 1.1 1.18 4 4 12 23 
22 19 M 1.63 86 32.37 106 104 1.02 126 80 76 68 55.8 44.2 1.26 1.15 4 16 1.24 1.24 -8 -4 6 25 
23 18 F 1.55 74 30.80 100 102 0.98 120 78 78 37 44.7 55.3 0.81 1.22 8 14 1.24 1.12 6 2 8 29 
24 18 F 1.5 78 34.67 113 115 0.98 118 72 86 47 74.5 25.5 2.92 1.14 12 18 1.14 1.19 14 8 16 37 
25 24 M 1.63 82 30.86 102 102 1.00 116 74 76 39 55.5 44.5 1.25 1.21 6 10 1.26 1.25 4 0 10 21 
MASTER CHART CASES 
S.NO 
AGE 
(YRS) 
SEX 
(M/F) 
Ht 
(m) 
Wt 
(Kg) 
BMI 
(kg/m2) 
WAIST 
(cms) 
HIP 
cms) 
WHR 
SBP 
(mm Hg) 
DBP 
(mm Hg) 
Mean 
HR 
(/min) 
SDNN 
(msec) 
LF 
nu 
HF nu LF/HF 
OST 
30/15 
ratio 
OST 
SBP1 
OST 
DBP1 
E/I 
ratio 
VR 
IHG 
SBP 
IHG 
DBP 
CPT 
DBP 
S.Leptin 
(ng/ml) 
26 20 M 1.53 80 34.17 111 114 0.97 124 72 84 55 69.4 30.6 2.27 0.92 4 14 1.02 1.17 8 4 10 35 
27 18 M 1.66 84 30.48 101 101 1.00 114 82 74 69 59.7 40.3 1.48 1.12 6 12 1.23 1.34 4 0 6 17 
28 19 F 1.49 70 31.53 104 110 0.95 128 82 82 54 62.3 37.5 1.66 1.21 10 18 1.21 1.14 6 4 12 39 
29 22 M 1.56 73 30.00 100 100 1.00 114 76 78 68 50.8 49.2 1.03 1.19 4 12 1.24 1.21 6 2 10 11 
30 19 F 1.59 73 28.88 98 100 0.98 114 74 72 64 36.6 63.3 0.58 1.14 8 14 1.42 1.49 -8 -2 8 21 
31 23 M 1.67 74 26.53 96 98 0.98 110 70 74 60 28.8 71.2 0.40 1.22 8 22 1.48 1.44 -4 0 14 16 
32 18 F 1.6 80 31.25 105 108 0.97 124 86 78 59 58.4 40.6 1.44 1.15 6 14 1.26 1.48 8 4 6 28 
33 23 F 1.47 71 32.86 106 107 0.99 122 84 82 57 63.2 36.8 1.72 0.86 10 16 1.17 1.17 10 6 8 35 
34 18 F 1.57 73 29.62 104 108 0.96 118 82 72 38 58.8 41.2 1.43 1.22 4 12 1.34 1.42 -6 -4 8 25 
35 21 M 1.52 80 34.63 113 113 1.00 124 82 78 46 68.5 31.5 2.17 0.78 6 24 1.16 1.16 14 8 12 33 
36 19 M 1.65 82 30.12 108 109 0.99 112 70 74 56 48.6 51.4 0.95 1.18 12 16 1.24 1.31 -4 0 10 13 
37 19 F 1.56 81 33.28 107 108 0.99 110 70 72 40 55.5 49.5 1.12 1.21 8 16 1.18 1.21 6 2 8 38 
38 24 M 1.45 72 34.24 116 115 1.01 118 72 83 52 59.4 41.5 1.43 0.86 6 12 1.24 1.22 10 4 6 18 
39 22 M 1.71 84 28.73 98 98 1.00 122 78 74 57 26.4 75.6 0.35 1.18 4 14 1.36 1.42 -2 0 8 15 
40 23 F 1.69 79 27.66 98 102 0.96 112 74 76 52 59.5 40.5 1.47 1.21 8 14 1.32 1.35 -8 -4 8 26 
41 23 F 1.53 78 33.32 110 109 1.01 126 72 84 56 64.2 34.7 1.85 0.98 6 8 1.15 1.16 8 4 14 24 
42 18 F 1.55 80 33.30 110 110 1.00 118 74 80 48 75.4 24.6 3.07 0.94 12 18 1.23 1.18 6 2 12 28 
43 21 M 1.6 84 32.81 104 104 1.00 114 78 76 53 49.8 50.2 0.99 1.18 14 20 1.33 1.3 -4 0 8 19 
44 19 M 1.62 87 33.15 109 105 1.04 114 76 82 57 53.2 43.8 1.21 1.14 8 14 1.16 1.42 10 4 12 22 
45 18 F 1.56 84 34.52 115 116 0.99 116 74 84 58 64.3 35.7 1.80 1.02 6 14 1.32 1.22 12 6 10 39 
46 24 M 1.65 88 32.32 109 107 1.02 110 74 74 45 58.4 41.6 1.40 1.22 8 12 1.28 1.19 -4 -4 16 26 
47 25 F 1.54 81 34.15 102 98 1.04 116 78 82 46 66.8 33.2 2.01 0.89 4 18 1.18 1.16 8 4 10 36 
48 18 M 1.53 81 34.60 117 120 0.98 122 80 74 51 68.4 31.6 2.16 1.04 6 12 1.24 1.21 14 10 6 29 
49 18 F 1.58 86 34.45 116 117 0.99 120 80 86 58 70.4 29.6 2.38 0.98 6 14 1.2 1.23 8 4 6 36 
50 22 M 1.59 75 29.67 103 103 1.00 120 84 74 53 34.8 65.2 0.53 1.19 4 10 1.32 1.38 -4 0 8 20 
